BMJ Open Outcome reporting from clinical trials of non-valvular atrial fibrillation treated with traditional Chinese medicine or Western medicine: a systematic review

Ruijin Qiu,¹ Jiayuan Hu,¹ Ya Huang,¹ Songjie Han,¹ Changming Zhong,¹ Min Li,¹ Tianmai He,¹ Yiyi Lin,¹ Manke Guan,¹ Jing Chen,² Hongcai Shang^{1,3}

To cite: Qiu R, Hu J, Huang Y, *et al.* Outcome reporting from clinical trials of non-valvular atrial fibrillation treated with traditional Chinese medicine or Western medicine: a systematic review. *BMJ Open* 2019;**9**:e028803. doi:10.1136/bmjopen-2018-028803

► Prepublication history and additional material for this paper are available online. To view these files, please visit the journal online (<http://dx.doi.org/10.1136/bmjopen-2018-028803>).

RQ and JH contributed equally.

Received 28 December 2018

Revised 22 June 2019

Accepted 09 July 2019

© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

For numbered affiliations see end of article.

Correspondence to

Jing Chen; cjshcsyc@126.com

Hongcai Shang;
shanghongcai@foxmail.com

ABSTRACT

Objectives To examine variation in outcomes, outcome measurement instruments (OMIs) and measurement times in clinical trials of non-valvular atrial fibrillation (NVAF) and to identify outcomes for prioritisation in developing a core outcome set (COS) in this field.

Design This study was a systematic review.

Data sources Clinical trials published between January 2015 and March 2019 were obtained from PubMed, the Cochrane Library, Web of Science, Wanfang Database, the China National Knowledge Infrastructure and SinoMed.

Eligibility criteria Randomised controlled trials (RCTs) and observational studies were considered. Interventions included traditional Chinese medicine and Western medicine. The required treatment duration or follow-up time was ≥ 4 weeks. The required sample size was ≥ 30 and ≥ 50 in each group in RCTs and observational studies, respectively. We excluded trials that aimed to investigate the outcome of complications of NVAF, to assess the mechanisms or pharmacokinetics, or for which full text could not be acquired.

Data extraction and synthesis The general information and outcomes, OMIs and measurement times were extracted. The methodological and outcome reporting quality were assessed. The results were analysed by descriptive analysis.

Results A total of 218 articles were included from 25 255 articles. For clinical trials of antiarrhythmic therapy, 69 outcomes from 16 outcome domains were reported, and 28 (31.82%, 28/88) outcomes were reported only once; the most frequently reported outcome was ultrasonic cardiogram. Thirty-one outcomes (44.93%, 31/69) were provided definitions or OMIs; the outcome measurement times ranged from 1 to 20 with a median of 3. For clinical trials of anticoagulation therapy, 82 outcomes from 18 outcome domains were reported; 38 (29.23%, 38/130) outcomes were reported only once. The most frequently reported outcome was ischaemic stroke. Forty (48.78%, 40/82) outcomes were provided OMIs or definitions; and the outcome measurement times ranged from 1 to 27 with a median of 8.

Conclusion Outcome reporting in NVAF is inconsistent. Thus, developing a COS that can be used in clinical trials is necessary.

Strengths and limitations of this study

- This systematic review is the first to describe variation in outcomes, outcome measurement instruments and outcome measurement time reporting in clinical trials for non-valvular atrial fibrillation (NVAF).
- The methodology is reproducible and transparent and has been assessed during a peer-review process.
- English and Chinese databases were searched, and randomised controlled trials and observational studies were considered.
- The aim of this review was to provide a list of outcomes for clinical trials of NVAF in traditional Chinese medicine, which is focused on Chinese herbal medicine therapy. Thus, clinical trials of surgery were not considered.

INTRODUCTION

According to a systematic review, atrial fibrillation (AF) is the main contributor to many diseases, such as ischaemic heart disease, stroke, renal disease and peripheral arterial disease. In addition, AF usually results in major cardiovascular events, cardiovascular and all-cause mortality, and sudden cardiac death.¹ Thus, treating AF is important.

There are different kinds of classifications for AF. According to the aetiology, AF can be classified as isolated AF, valvular AF, non-valvular AF (NVAF) and so on. NVAF refers to AF occurring without rheumatic mitral stenosis, mechanical/bioprosthetic or mitral valve repair.² According to the characteristics and timing of AF onset, AF can be classified as first diagnosed AF, paroxysmal AF, persistent AF, long-standing persistent AF and permanent AF.³

Current evidence has shown that catheter ablation and drug therapy are beneficial for controlling heart rhythm, maintaining ventricular rate, and preventing thrombosis and stroke. However, the arrhythmogenic

Figure 1 The flowchart of the systematic review.

effects and risk of death after taking antiarrhythmic drugs cannot be ignored. With the increasing number of traditional Chinese medicine (TCM) clinical trials in treating AF, the efficacy and safety of TCM have been proven.⁴ However, there are some problems in these TCM clinical trials; for example, similar clinical trials reported different outcomes. Therefore, some trials cannot be included in systematic reviews/meta-analyses because of outcome reporting heterogeneity. In TCM clinical trials, the long-term outcomes, patient-reported outcomes and safety outcome reporting are limited; thus, these trials cannot provide appropriate evidence for TCM in treating AF. Developing a core outcome set (COS) may resolve these problems.

A COS is a minimum set that should be measured and reported in all clinical trials for a specific condition.⁵ According to the characteristics and advantages of TCM, we intend to develop a COS for TCM clinical trials for NVAf, with registered⁶ and published⁷ protocols.

According to the study protocol, conducting a systematic review is the first step in the development of a COS for NVAf to develop a long list of outcomes. In this research, we will report the results of the systematic review, including assessing the quality of outcome reporting and the quality of trials, as well as examining the variation in outcome reporting, outcome measurement instrument (OMI) reporting and measurement time point reporting.

METHODS

Search strategy

In clinical trials and clinical practice, TCM, especially Chinese herbal medicine therapy is often used as an

adjuvant therapy in internal medicine treatment; thus, obtaining a comprehensive list of outcomes for TCM clinical trials is difficult. In this systematic review, we focused on clinical trials of TCM, integrated medicine and Western medicine in internal medicine. The literature database included PubMed, the Cochrane Library, Web of Science, Wanfang database, the China National Knowledge Infrastructure and SinoMed. A literature search was conducted two times. The first search was conducted from January 2015 to June 2017, and the second search was conducted from May 2017 to March 2019. The search strategy for English databases is shown in online supplementary additional file 1.

Inclusion criteria

According to the protocol, both randomised controlled trials (RCTs) and observational studies were considered. Patients with NVAf who accepted interventions including TCM or Western medicines were eligible. The required treatment duration or follow-up time was ≥ 4 weeks. For RCTs, the required number of participants was ≥ 30 in each group. For observational studies, the required number of participants was ≥ 50 .

Exclusion criteria

We excluded clinical trials that aimed to investigate the outcome of complications of NVAf, to assess the mechanism of drug action or pharmacokinetics, or for which full text could not be acquired.

Methodological quality has little influence on developing a long list of outcomes in the development of a COS. However, we excluded some studies with serious problems, such as a Jadad score of 0 for RCTs, contradictions

Table 1 The characteristics of included articles

Study ID	Study type	Country	Patients recruited	Course of treatment	Follow-up duration	Quality of outcome reporting	Quality of study	Interventions	Comparisons
Kang ¹⁷	RCT	China	98	1 Year	/	2	2/5	Triple antithrombotic therapy+CT	Dual antithrombotic therapy+CT
Guo <i>et al</i> ¹⁸	RCT	China	62	/	1 Year	2	2/5	Atorvastatin+CT	CT
Li <i>et al</i> ¹⁹	RCT	China	76	8–10 Days	6 Months	0	2/5	Amiodarone+dabigatran	Warfarin
Bu <i>et al</i> ²⁰	RCT	China	192	/	1 Year	2	3/5	Low-dose warfarin	Normal-dose warfarin
Pan and Liu ²¹	RCT	China	90	6 Months	/	0	3/5	Candesartan+rosuvastatin	CT+candesartan
Li ²²	RCT	China	80	4 Weeks	1 Year	2	2/5	Dabigatran+CT	Warfarin+CT
Chen <i>et al</i> ²³	RCT	China	80	/	1 Year	2	2/5	Warfarin+CT	Aspirin+CT
Sang <i>et al</i> ²⁴	RCT	China	80	/	1 Year	2	2/5	Valsartan+rosuvastatin+CT	CT
Guo ²⁵	RCT	China	60	1 Month	6 Months	2	2/5	Amiodarone+irbesartan	Amiodarone
Zuo <i>et al</i> ²⁶	RCT	China	180	/	3 Months	2	3/5	Dabigatran	Warfarin
Liu, <i>et al</i> ²⁷	RCT	China	140	/	1 Year	0	2/5	Dabigatran	Warfarin
Yang ²⁸	RCT	China	120	/	1 Year	0	2/5	Amlodipine+amiodarone	Candesartan+amiodarone
Li <i>et al</i> ²⁹	RCT	China	60	3 Months	/	0	2/5	Candesartan+amiodarone	Amiodarone
Yang <i>et al</i> ³⁰	RCT	China	88	2 Months	/	0	3/5	Sotalol+irbesartan	Sotalol
Li <i>et al</i> ³¹	CoS	China	74	4 Weeks	/	0	5/9	Valsartan	Hydrochlorothiazide
Lin <i>et al</i> ³²	RCT	China	120	6 Months	6 Months	2	2/5	Rosuvastatin+CT	CT
Qin <i>et al</i> ³³	RCT	China	360	/	2 Years	0	2/5	Warfarin	Aspirin
Qin <i>et al</i> ³⁴	RCT	China	360	/	2 Years	0	2/5	Low-dose warfarin	High-dose warfarin; aspirin
Chen <i>et al</i> ³⁵	RCT	China	77	1 Year	/	0	2/5	Dabigatran+clopidogrel	Warfarin
Wang <i>et al</i> ³⁶	RCT	China	150	/	1 Year	3	2/5	Aspirin+warfarin	Aspirin; warfarin
Liu and Zhang ³⁷	RCT	China	150	3 Months–1 year	/	0	2/5	Low-dose warfarin	High-dose warfarin; aspirin
Zhang ³⁸	RCT	China	118	/	1 Year	0	2/5	Irbesartan+CT	Irbesartan
Zhang ³⁹	RCT	China	120	/	30 Days	0	2/5	Amiodarone	Propafenone
Huang <i>et al</i> ⁴⁰	RCT	China	76	1 Year	/	2	2/5	Irbesartan+amiodarone+CT	Amiodarone+CT
Xu <i>et al</i> ⁴¹	RCT	China	234	/	2 Years	0	2/5	Aspirin	Low-dose warfarin; high-dose warfarin
Lin ⁴²	RCT	China	158	/	10 Months	0	2/5	Candesartan+amiodarone+CT	Amiodarone+CT
Zhang and Zong ⁴³	RCT	China	62	/	3 Months	0	2/5	High-dose warfarin	Normal-dose warfarin
Guo ⁴⁴	RCT	China	100	1 Year	/	0	2/5	Amiodarone+irbesartan	Amiodarone+metoprolol
Zhang ⁴⁵	RCT	China	160	1 Year	/	0	3/5	Indapamide+valsartan+CT	Valsartan+CT
Yang and Yao ⁴⁶	RCT	China	150	3 Months	/	0	3/5	Methimazole+bisoprolol+CT	Bisoprolol+CT

Continued

Table 1 Continued

Study ID	Study type	Country	Patients recruited	Course of treatment	Follow-up duration	Quality of outcome reporting	Quality of study	Interventions	Comparisons
Zhang and Gu ⁴⁷	RCT	China	70	/	3 Months	0	2/5	Amiodarone +CT	Amiodarone+deacetyl glucoside
Hou and Liu ⁴⁸	RCT	China	136	1 Year	/	0	2/5	Amiodarone+irbesartan	Amiodarone
Jiang and Xu ⁴⁹	RCT	China	70	4 Weeks	11 Months	0	2/5	Valsartan+amiodarone+CT	Amiodarone+CT
Song et al ⁵⁰	RCT	China	120	1 Year	/	0	3/5	Amiodarone+fosinopril	Amiodarone
Wang and Yuan ⁵¹	RCT	China	76	4 Weeks	/	0	2/5	Bisoprolol+CT	Amiodarone+CT
Yan et al ⁵²	RCT	China	96	/	2 Years	0	2/5	Propafenone+CT	Amiodarone+CT
Zhang and Yin ⁵³	RCT	China	92	1 Year	/	2	2/5	Irbesartan+amiodarone	Amlodipine+amiodarone
Jian ⁵⁴	RCT	China	68	/	3 Months	0	2/5	Warfarin	Aspirin
Huang and Qin ⁵⁵	RCT	China	60	/	2 Years	0	2/5	Dabigatran	Warfarin
Yang ⁵⁶	RCT	China	180	1 Year	/	2	3/5	Rosuvastatin+amiodarone+CT	Amiodarone+CT
Liu et al ⁵⁷	RCT	China	91	/	2 Years	2	2/5	Moderate-dose warfarin	Low-dose warfarin
Zhou et al ⁵⁸	RCT	China	120	6 Months	/	0	3/5	High-dose atorvastatin	Low-dose atorvastatin
Chen ⁵⁹	RCT	China	96	6 Months	/	0	3/5	Enalapril+amiodarone	Amiodarone
Wang and Jin ⁶⁰	RCT	China	176	6 Months	/	0	3/5	High-dose rosuvastatin	Normal-dose rosuvastatin
Ou et al ⁶¹	RCT	China	88	/	6 Months	0	2/5	Atorvastatin+CT	CT
Geng et al ⁶²	RCT	China	198	/	10–20mMonths	0	2/5	Aspirin+dipyridamole	Aspirin
Chu ⁶³	RCT	China	90	1 Year	/	0	2/5	Amiodarone+benapril	Amiodarone
Zhu ⁶⁴	RCT	China	86	3 Months	/	0	2/5	Candesartan+amiodarone	Amiodarone
Lin ⁶⁵	RCT	China	90	1 Year	/	0	3/5	Amiodarone+telmisartan	Amiodarone
Duan et al ⁶⁶	RCT	China	80	/	1 Year	0	2/5	Amiodarone+spironolactone	Amiodarone
Lu et al ⁶⁷	RCT	China	64	/	2 Months	0	3/5	Dabigatran	Warfarin
Wei and Li ⁶⁸	RCT	China	120	6 Months	/	2	2/5	High-dose dabigatran +warfarin	Low-dose dabigatran+warfarin
Su et al ⁶⁹	RCT	China	74	/	6 Months	0	3/5	Amiodarone	Cedilanid
Yu ⁷⁰	RCT	China	82	12 Weeks	/	2	3/5	Irbesartan+amiodarone	Amiodarone
Li et al ⁷¹	RCT	China	108	1 Year	/	2	2/5	Perindopril+amiodarone+CT	CT
Wen ⁷²	RCT	China	80	/	2 Years	0	2/5	Low-dose aspirin	High-dose aspirin
Chen ⁷³	RCT	China	200	/	1 Year	2	2/5	Low-dose warfarin	High-dose warfarin

Continued

Table 1 Continued

Study ID	Study type	Country	Patients recruited	Course of treatment	Follow-up duration	Quality of outcome reporting	Quality of study	Interventions	Comparisons
Xu <i>et al</i> ⁷⁴	RCT	China	200	/	1 Year	0	2/5	Metoprolol; metoprolol+spironolactone; metoprolol+valsartan	No treatment
Huang <i>et al</i> ⁷⁵	RCT	China	153	1 Year	/	2	3/5	Rosuvastatin+amiodarone + CT	Amiodarone+CT
Zhao and Dong ⁷⁶	RCT	China	98	1 Year	/	0	3/5	Atorvastatin+CT	CT
Feng <i>et al</i> ⁷⁷	RCT	China	64	4 Weeks	/	0	2/5	Maixuekang+warfarin+CT	CT+warfarin
Bo <i>et al</i> ⁷⁸	RCT	China	160	1 Month	6 Months	2	2/5	Amiodarone+wenxin granule	Amiodarone
Zhang and Peng ⁷⁹	RCT	China	80	30 Days	/	2	3/5	CT+modified Buuyang huanwu decoction	CT
Chen <i>et al</i> ⁸⁰	RCT	China	60	3 Months	/	2	2/5	Jianxin pinglv pill+warfarin+metoprolol	Warfarin+metoprolol
Cao <i>et al</i> ⁸¹	RCT	China	220	4 Weeks	/	2	3/5	CT+shensong yangxin capsule	CT
Chang and Zhou ⁸²	RCT	China	88	8 Weeks	/	2	3/5	Atorvastatin+wenxin granule+CT	CT+amiodarone
Fan ⁸³	RCT	China	112	6 Months	/	0	1/5	Losartan+amiodarone +shensong yangxin capsule	Losartan+amiodarone
Ye ⁸⁴	RCT	China	80	4 Weeks	/	0	2/5	Wenxin granule+propafenone	Propafenone
Wang ⁸⁵	RCT	China	60	3 Months	/	0	2/5	Taoren honghua decoction+warfarin	Warfarin
Cheng <i>et al</i> ⁸⁶	RCT	China	200	180 Days	/	0	3/5	Yangxin guicao decoction+CT	CT
Han <i>et al</i> ⁸⁷	RCT	China	60	4 Weeks	/	2	3/5	Xifeng Zhiji decoction+metoprolol	Metoprolol
Peng ⁸⁸	RCT	China	96	1 Year	/	0	2/5	CT+Amiodarone+shexiang baixin pill	CT+amiodarone
Zhang ⁸⁹	RCT	China	180	12 Weeks	/	2	2/5	Wenxin granule+CT	CT
Pan <i>et al</i> ⁹⁰	RCT	China	65	3 Months	/	0	2/5	Amiodarone+jianxin pinglv pill	Amiodarone
Huang ⁹¹	RCT	China	120	1 Year	/	0	2/5	CT+valsartan+dabuyuan decoction	CT+valsartan
Li <i>et al</i> ⁹²	RCT	China	90	1 Month	/	0	3/5	Shensong yangxin capsule+Amiodarone + CT	Amiodarone+CT
Wang and Wang ⁹³	RCT	China	72	3 Months	/	0	3/5	Wenxin granule+CT	CT
Cui ⁹⁴	RCT	China	80	8 Weeks	/	2	2/5	Zhigancao decoction+metoprolol	Metoprolol
Bi ⁹⁵	RCT	China	70	8 Weeks	/	0	3/5	Dingxin granule	Amiodarone

Continued

Study ID	Study type	Country	Patients recruited	Course of treatment	Follow-up duration	Quality of outcome reporting	Quality of study	Interventions	Comparisons
Zhang ⁹⁶	RCT	China	116	24 Weeks	/	0	3/5	Shensong yangxin capsule+CT	CT
Chen <i>et al</i> ⁹⁷	RCT	China	60	4 Weeks	/	2	3/5	Zhigancao decoction+amiodarone	Amiodarone
Liu <i>et al</i> ⁹⁸	RCT	China	68	4 Weeks	/	2	2/5	Dingxin granule+metoprolol	Metoprolol
Zhang ⁹⁹	RCT	China	84	6 Months	/	0	1/5	CT+amiodarone+wenxin granule	CT+amiodarone
Granger <i>et al</i> ¹⁰⁰	RCT	International	13397	1–4 Years	/	4	3/5	Apixaban	Warfarin
Held <i>et al</i> ¹⁰¹	RCT	International	18201	1–4 Years	/	4	3/5	Apixaban	Warfarin
Jaspers <i>et al</i> ¹⁰²	RCT	International	18201	1–4 Years	30 Months*	5	3/5	Apixaban	Warfarin
Bahit <i>et al</i> ¹⁰³	RCT	International	18140	1–4 Years	/	2	3/5	Edoxaban	Warfarin
Alexander <i>et al</i> ¹⁰⁴	RCT	International	17370	1–4 Years	1.8 Yearst	2	3/5	Higher-dose edoxaban; lower-dose edoxaban	Warfarin
Hu <i>et al</i> ¹⁰⁵	RCT	International	18201	1–4 Years	1 Year	4	3/5	Aapixaban	Warfarin
Pengo <i>et al</i> ¹⁰⁶	RCT	Italy	180	/	≥30 Days	2	3/5	Pharmacogenetic warfarin dosing	Standard warfarin dosing
Steffel <i>et al</i> ¹⁰⁷	RCT	International	2492	907 Dayst	2.8 Yearst	1	5/5	Edoxaban	Warfarin
Yamashita <i>et al</i> ¹⁰⁸	RCT	International	1943	907 Dayst	2.8 Yearst	6	5/5	Warfarin	Edoxaban
Kato <i>et al</i> ¹⁰⁹	RCT	International	21105	907 Dayst	2.8 Yearst	4	5/5	Higher-dose edoxaban; lower-dose edoxaban	Warfarin
Meng <i>et al</i> ¹¹⁰	RCT	China	180	/	12 Months	3	3/5	Wenxin granule	Sotalol
Wang <i>et al</i> ¹¹¹	RCT	China	151	1 Year	1 Year	4	3/5	Aspirin+naoxintong capsule	Warfarin
Brambatti <i>et al</i> ¹¹²	RCT	USA	18113	/	2 Years	3	5/5	Dabigatran	Warfarin
Verdecchia <i>et al</i> ¹¹³	RCT	USA	10372	/	2 Years	3	5/5	Dabigatran	Warfarin
Tan <i>et al</i> ¹¹⁴	RCT	China	126	/	2 Years	2	5/5	Fluvastati	Placebo
Shah <i>et al</i> ¹¹⁵	RCT	International	5205	1 Year	668 Dayst	2	3/5	Aspirin	Rivaroxaban
Sun <i>et al</i> ¹¹⁶	RCT	International	14236	1 Year	668 Dayst	2	3/5	Rivaroxaban	Warfarin
Yao <i>et al</i> ¹¹⁷	RCT	China	92	1 Year	/	0	3/5	Fluvastatin+benazepril	Fluvastatin
Goette <i>et al</i> ¹¹⁸	RCT	International	2199	28 Days	30 Days	4	3/5	Edoxaban	Enoxaparin-warfarin
Magnani <i>et al</i> ¹¹⁹	RCT	International	14071	907 Days	2.8 Years	5	5/5	Edoxaban	Warfarin
Senoo <i>et al</i> ¹²⁰	RCT	UK	4556	/	11.6 Months	3	3/5	SR34006	Warfarin or acenocoumarol
Hijazi <i>et al</i> ¹²¹	RCT	International	16869	1 Year	/	4	3/5	Apixaban	Warfarin
Cadrin <i>et al</i> ¹²²	RCT	Canada	1376	/	37 Monthst	3	4/5	Rhythm control	Rate control therapy

Continued

Table 1 Continued

Study ID	Study type	Country	Patients recruited	Course of treatment	Follow-up duration	Quality of outcome reporting	Quality of study	Interventions	Comparisons
Maciag <i>et al</i> ¹²³	RCT	Poland	74	/	/	5	4/5	Antazoline	Control
Ng <i>et al</i> ¹²⁴	RCT	International	5599	/	1.1 Years	4	4/5	Apixaban	Acetylsalicylic acid
Inoue <i>et al</i> ¹²⁵	RCT	Japan	127	2 Weeks	/	5	3/5	5 mg fixed dose β -Blockers	10 mg dose-escalation group; 20 mg dose-escalation group
Dong <i>et al</i> ¹²⁶	RCT	China	79	/	19.84 Months†	2	2/5	Intravenous ibutilide	Intravenous amiodarone+intravenous ibutilide
Hong <i>et al</i> ¹²⁷	RCT	South Korea	183	4 Weeks	7 Days	4	5/5	Rivaroxaban	Warfarin sodium
Tan <i>et al</i> ¹²⁸	RCT	China	118	2 Years	/	2	2/5	Fluvastatin+CT	CT
Zhang <i>et al</i> ¹²⁹	RCT	China	120	1 Year	/	0	2/5	CT+low-dose rosuvastatin; CT+high-dose rosuvastatin	CT
Zhou <i>et al</i> ¹³⁰	RCT	China	186	6 Months	/	2	3/5	Telmisartan	Non-ARB and non-ACEI
Qian <i>et al</i> ¹³¹	RCT	China	85	4 Weeks	/	0	3/5	TGM+CT	CT
Di <i>et al</i> ¹³²	RCT	China	50	6 Months	/	3	2/5	Telmisartan+amiodarone	Amiodarone
Liu ¹³³	RCT	China	200	2 Months	/	0	3/5	Valsartan	Nifedipine
Yu <i>et al</i> ¹³⁴	RCT	China	146	/	1 Year	2	2/5	Amiodarone +rosuvastatin+valsartan	Amiodarone+valsartan
Zhang and Jiao ¹³⁵	RCT	China	158	/	1–2 Years	2	2/5	Warfarin+CGA	Warfarin
Li <i>et al</i> ¹³⁶	RCT	China	120	1 Year	/	0	1/5	Telmisartan+CT	Amlodipine+CT
Pang <i>et al</i> ¹³⁷	RCT	China	60	6 Months	/	2	2/5	Valsartan	Amlodipine
Wang ¹³⁸	RCT	China	126	12 Weeks	/	2	3/5	Atorvastatin+irbesartan+CT	Irbesartan+CT
Yan <i>et al</i> ¹³⁹	RCT	China	124	1 Year	/	0	3/5	Benapril+amiodarone+CT	Amiodarone+CT
Huang <i>et al</i> ¹⁴⁰	RCT	China	125	6 Months	/	2	2/5	Valsartan+CT	Nifedipine+CT
Yuan and Liu ¹⁴¹	RCT	China	92	1 Year	/	2	2/5	Candesartan+CT	CT
Chen <i>et al</i> ¹⁴²	RCT	China	102	/	1 Year	2	2/5	Rivaroxaban	Warfarin
Tu ¹⁴³	RCT	China	124	/	1 Year	0	2/5	Warfarin	Aspirin
Bassand <i>et al</i> ¹⁴⁴	CoS	International	17 162	/	2 Years	0	7/9	Antithrombotic treatment	
Haas <i>et al</i> ¹⁴⁵	CoS	International	9934	/	1 Year	0	7/9	VKAs	
Chan <i>et al</i> ¹⁴⁶	CoS	China	571	/	2.6 Years*	4	5/9	Dabigatran	Warfarin
Chan <i>et al</i> ¹⁴⁷	CoS	China	2153	/	4.2 Years*	4	6/9	Dabigatran	Warfarin
Xie <i>et al</i> ¹⁴⁸	CoS	USA	127 068	/	30 days	2	7/9	Apixaban	Warfarin
Bengtson <i>et al</i> ¹⁴⁹	CoS	USA	61 648	/	15 Months†	4	5/9	Dabigatran; rivaroxaban	Warfarin

Continued

Table 1 Continued

Study ID	Study type	Country	Patients recruited	Course of treatment	Follow-up duration	Quality of outcome reporting	Quality of study	Interventions	Comparisons
Chan <i>et al</i> ¹⁵⁰	CS	China	115	/	4 Weeks	4	14/20	Warfarin; aspirin; or dabigatran	
Hohnloser <i>et al</i> ¹⁵¹	CoS	Germany	35013	/	218–280 Days	4	5/9	Phenprocoumon; anticoagulants	
Saji <i>et al</i> ¹⁵²	CoS	Japan	235	/	30 Days	2	7/9	NOACs	Warfarin
Korenstra <i>et al</i> ¹⁵³	CoS	Netherlands	920	/	2 Years	5	8/9	Dabigatran	Acenocoumarol
Naganuma <i>et al</i> ¹⁵⁴	CoS	Japan	362	/	1.3 Years	3	8/9	Dabigatran	Warfarin
Sunbul <i>et al</i> ¹⁵⁵	CoS	Turkey	171	/	1 Year	2	7/9	Coumadin; dabigatran; rivaroxaban	
Yao <i>et al</i> ¹⁵⁶	CoS	USA	76354	/	0.5–0.7 Year*	3	4/9	Dabigatran; rivaroxaban; apixaban	Warfarin
Ezekowitz <i>et al</i> ¹⁵⁷	RCT	USA	5851	/	4.6 Years†	3	5/5	Dabigatran 150 mg	Dabigatran 110 mg
Camm <i>et al</i> ¹⁵⁸	CS	UK	6785	/	1 Year	5	17/20	Rivaroxaban	
Marquez-Contreras <i>et al</i> ¹⁵⁹	CS	Spain	412	/	1 Year	2	14/20	Rivaroxaban	
Tepper <i>et al</i> ¹⁶⁰	CoS	USA	45338	/	1.1 Years†	1	9/9	Warfarin	
Li <i>et al</i> ¹⁶¹	CoS	USA	76940	/	1 Year	2	8/9	Warfarin	Apixaban
Marquez <i>et al</i> ¹⁶²	CS	Spain	412	/	1 Year	2	14/20	Rivaroxaban	
Larsen <i>et al</i> ¹⁶³	CoS	Denmark	61 678	/	2.5 Years	2	6/9	Non-vitamin K antagonist oral anticoagulants	Warfarin
Kilickiran <i>et al</i> ¹⁶⁴	CoS	Turkey	294	280–336 days	/	3	6/9	Dabigatran	Rivaroxaban
Inoue <i>et al</i> ¹⁶⁵	CoS	Japan	6148	/	2 Years	2	4/9	Dabigatran	
Chan <i>et al</i> ¹⁶⁶	CoS	China	5426	/	3.6 Years*	2	5/9	Warfarin	Aspirin; no therapy
Laliberte <i>et al</i> ¹⁶⁷	CoS	Canada	13049	/	114 and 123.7 Days*	3	4/9	Rivaroxaban	Warfarin
Lee <i>et al</i> ¹⁶⁸	CoS	Korea	321	/	2.3 Months*	3	6/9	VKAs	
Lau <i>et al</i> ¹⁶⁹	CoS	China	8152	/	501 Days*	0	6/9	Dabigatran	Warfarin
Ho <i>et al</i> ¹⁷⁰	CoS	China	8754	/	3 Years*	4	5/9	Aspirin	Dabigatran; warfarin
Chan <i>et al</i> ¹⁷¹	CoS	China	9727	/	2 Years	2	7/9	Warfarin	Aspirin
Chao <i>et al</i> ¹⁷²	CoS	China	101243	/	4.9 Years*	0	7/9	Betablockers	Calcium channel blockers; digoxin

Continued

Table 1 Continued

Study ID	Study type	Country	Patients recruited	Course of treatment	Follow-up duration	Quality of outcome reporting	Quality of study	Interventions	Comparisons
Pastori <i>et al</i> ¹⁷³	CoS	Italy	815	/	33.2 Months†	2	6/9	Digoxin	
Chen <i>et al</i> ¹⁷⁴	CoS	China	10384	/	3.2 Years	2	6/9	Anticoagulation and antiplatelet therapy	
Engelberger <i>et al</i> ¹⁷⁵	CoS	Switzerland	537	/	3 Months	4	5/9	Rivaroxaban	
Li <i>et al</i> ¹⁷⁶	RCT	China	137	/	1 Year	0	2/5	Low-dose warfarin	Unclear
Tung <i>et al</i> ¹⁷⁷	CS	Canada	148 446	/	5 Years	1	10/20	Warfarin	
Wu <i>et al</i> ¹⁷⁸	CoS	China	4638	/	2.4 Years†	4	8/9	Statin	Non-statin
Kodani <i>et al</i> ¹⁷⁹	CoS	Japan	6616	/	5 Years	1	6/9	Warfarin; NOACs	No anticoagulation therapy
Yamashita <i>et al</i> ¹⁸⁰	CoS	Japan	6404	/	2 Years	0	7/9	Warfarin	
Kumagai <i>et al</i> ¹⁸¹	CoS	Japan	6404	/	2 Years	0	7/9	Warfarin+statin	Warfarin alone
Blin <i>et al</i> ¹⁸²	CoS	France	8894	/	28–29 Months	2	8/9	VKAs:	
Piccini <i>et al</i> ¹⁸³	CoS	USA	10135	/	2.3 Years†	0	5/9	Unclear	
Allen <i>et al</i> ¹⁸⁴	CoS	USA	9619	/	22 Months*	3	7/9	Digoxin	
Genovesi <i>et al</i> ¹⁸⁵	CoS	Italy	290	/	2 Years	0	7/9	Warfarin	
Qin <i>et al</i> ¹⁸⁶	CoS	USA	5952	/	26.1 Months	4	7/9	Antiarrhythmic drugs	
Purmah <i>et al</i> ¹⁸⁷	CoS	International	3119	/	1 Year	2	7/9	Rate control	Rhythm control
Pasca <i>et al</i> ¹⁸⁸	CS	Italy	143	/	1 Year	2	15/20	Oral anticoagulant therapy	No oral anticoagulant therapy
Nielsen <i>et al</i> ¹⁸⁹	CoS	Denmark	55644	/	2.3 Years*	1	8/9	NOACs	Warfarin
Bo <i>et al</i> ¹⁹⁰	CoS	Italy	452	/	300.5 Days*	2	7/9	Oral anticoagulant therapy	No oral anticoagulant therapy
Jacobs <i>et al</i> ¹⁹¹	CoS	USA	5254	/	243 Days*	2	7/9	DOACs	Warfarin
Lip <i>et al</i> ¹⁹²	CoS	International	29338	/	90–127 Days	2	8/9	Warfarin	Apixaban, dabigatran or rivaroxaban.
Hanon <i>et al</i> ¹⁹³	CS	France	405	/	6 Months	4	14/20	Rivaroxaban	
Patti <i>et al</i> ¹⁹⁴	CoS	International	6412	/	1 Year	2	8/9	Antithrombotic therapies	
Graham <i>et al</i> ¹⁹⁵	CoS	USA	118891	/	108 and 111 Days*	4	6/9	Dabigatran	Rivaroxaban
Tampieri <i>et al</i> ¹⁹⁶	CS	Italy	218	/	30 Days	1	15/20	Anticoagulation	
Lee <i>et al</i> ¹⁹⁷	CoS	South Korea	754	/	3.2–3.5 years*	2	7/9	VKAs	No vitamin K antagonist
Stolk <i>et al</i> ¹⁹⁸	CoS	Netherlands	30 146	/	1–3 Years	2	5/9	DOACs; VKAs; low-dose aspirin or mixed users	
Boriani <i>et al</i> ¹⁹⁹	CoS	International	2589	/	1 Year	2	7/9	According to AF type	

Continued

Table 1 Continued

Study ID	Study type	Country	Patients recruited	Course of treatment	Follow-up duration	Quality of outcome reporting	Quality of study	Interventions	Comparisons
Eisen <i>et al</i> ²⁰⁰	RCT	International	21 105	907 Days [#]	2.8 Years [#]	3	7/9	Digoxin	No Digoxin
Wan and Deng ²⁰¹	RCT	China	292	3 Months	3 Months	0	2/5	Dabigatran+clopidogrel	Clopidogrel
Jian ²⁰²	RCT	China	128	3 Months	/	0	2/5	Dabigatran+CT	Warfarin+CT
Gao ²⁰³	RCT	China	71	/	1 Year	0	3/5	Low-dose warfarin	Normal-dose warfarin
Wang ²⁰⁴	RCT	China	84	/	1 Year	0	3/5	Warfarin	Warfarin
DM Zhang and HM Zhang ²⁰⁵	RCT	China	81	/	1 Year	0	2/5	Warfarin	Warfarin
Hadiagaowa <i>et al</i> ²⁰⁶	RCT	China	146	6 Months	/	2	3/5	Rivaroxaban+CT	Warfarin+CT
Chen <i>et al</i> ²⁰⁷	RCT	China	86	1 Year	/	2	3/5	Rivaroxaban+CT	Warfarin+CT
Chen <i>et al</i> ²⁰⁸	RCT	China	160	/	6 Months	2	1/5	Maixuekang capsule	Aspirin
Li and Yue ²⁰⁹	RCT	China	76	4 Weeks	/	0	3/5	TCM+dabigatran+aspirin	Dabigatran+aspirin
Yu ²¹⁰	RCT	China	80	4 Weeks	/	0	2/5	Xuefu Zhuyu decoction+dabigatran	Dabigatran
RR <i>et al</i> ²¹¹	RCT	International	245	/	1 Year	5	5/5	Targeted therapy+CT	CT
Ezekowitz <i>et al</i> ²¹²	RCT	International	1500	/	30 and 90 Days*	2	3/5	Apixaban	Heparin/VKA
Li X <i>et al</i> ²¹³	RCT	China	66	/	6 Months	1	2/5	Genotype-based anticoagulant therapy with warfarin	Routine warfarin therapy
Yamashita <i>et al</i> ²¹⁴	RCT	Japan	220	4 weeks	/	4	2/5	Bisoprolol transdermal patch	Bisoprolol fumarate oral formulation
Bartlett <i>et al</i> ²¹⁵	CoS	USA	286	12.4 monthst	16.5 Months†	6	7/9	Rivaroxaban with concomitant diltiazem	Rivaroxaban
Andersson <i>et al</i> ²¹⁶	CoS	Denmark	9212	/	1 Year	2	8/9	Dabigatran	Warfarin
Deitelzweig <i>et al</i> ²¹⁷	CoS	USA	25857	/	5–6 Monthst	1	8/9	Apixaban	Rivaroxaban, dabigatran, warfarin
Friberg and Oldgren ²¹⁸	CoS	Sweden	68056	/	0.71 and 1.74 Years†	3	8/9	NOAC	Warfarin
Hernandez <i>et al</i> ²¹⁹	CoS	USA	41 336	/	185–294 Days*	5	8/9	Apixaban;dabigatran; rivaroxaban; warfarin	Never used oral anticoagulation
Pohjantahti <i>et al</i> ²²⁰	CoS	Finland	200	/	1 Year	6	7/9	Vernakalant	Flecainide
Koretsune <i>et al</i> ²²¹	CoS	Japan	18261	/	1 Year	5	8/9	Dabigatran	Warfarin

Continued

Table 1 Continued

Study ID	Study type	Country	Patients recruited	Course of treatment	Follow-up duration	Quality of outcome reporting	Quality of study	Interventions	Comparisons
Lai <i>et al</i> ²²²	CoS	China	2592	/	3.86–4.95 Years*	3	8/9	Amiodarone; amiodarone+digoxin	Digoxin
Li WH <i>et al</i> ²²³	CoS	China	2099	/	21.7 Months*	6	8/9	Warfarin	Rivaroxaban; dabigatran
Link <i>et al</i> ²²⁴	CoS	International	21 099	907 Days*	1022 Days†	5	7/9	Warfarin	High-dose edoxaban; low-dose edoxaban
Lip <i>et al</i> ²²⁵	CoS	Denmark	14 020	/	2.6 Years*	3	8/9	Apixaban; dabigatran; rivaroxaban	Warfarin
Noseworthy <i>et al</i> ²²⁶	CoS	USA	107 373	/	3 Years	2	8/9	Warfarin	Apixaban; dabigatran; rivaroxaban
Lip <i>et al</i> ²²⁷	CoS	USA	321 182	/	1 Year	4	8/9	Apixaban; warfarin; dabigatran; rivaroxaban	Warfarin
Martinez <i>et al</i> ²²⁸	CoS	The USA	6836	/	1.4 Year†	3	8/9	Rivaroxaban	Warfarin
Gielsing <i>et al</i> ²²⁹	CoS	The UK	31 497	/	0.95–2.94 Years*	6	8/9	NOACs; VKA; aspirin; mixed	Warfarin
Go <i>et al</i> ²³⁰	CoS	The USA	50 578	66 Days†	102–123 Days*	3	8/9	Dabigatran	Warfarin
Forslund <i>et al</i> ²³¹	CoS	Sweden	22 198	/	1.07 and 1.61 Years*	6	8/9	Dabigatran; rivaroxaban; apixaban	Warfarin
Sjlander <i>et al</i> ²³²	CoS	Sweden	64 382	208–407 Days*	/	3	8/9	Dabigatran; rivaroxaban; apixaban	Warfarin
Corbalan <i>et al</i> ²³³	CoS	International	21 105	/	2.8 Years	5	8/9	Edoxaban	Warfarin
Bae <i>et al</i> ²³⁴	CS	Korea	1350	/	3 Years	3	16/20	Non-VKA	VKA

*Mean follow-up.

†Median follow-up.

ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin II receptor antagonist; CGA, comprehensive geriatric assessment; CS, case series; CT, conventional therapy; CoS, cohort study; DOACs, direct oral anticoagulants; NOACs, non-vitamin K antagonist oral anticoagulants; TCM, traditional Chinese medicine; VKAs, vitamin K antagonists.

Figure 2 The type and distribution of clinical trials.

in the research or the authors are in the institutions who do not have the ability to conduct RCTs in China.

Study identification

Two reviewers (RQ and SH) independently assessed the titles and abstracts from searches. Then, the full texts of the potential articles were retrieved and assessed for further identification. Any disagreement was resolved by discussion or consulting the third investigator (HS).

Data extraction

Two reviewers (RQ and JH) independently extracted information. The information included the first author's name, publication time, number of participants, country of authors (if the authors are from different countries, it was stated as 'international'), interventions, comparisons, course of treatment, follow-up duration, outcomes, the definition of outcomes, OMIs and measurement time (intervention duration or follow-up time). Any

disagreement was resolved by discussion or consulting the third investigator (HS).

In addition, we assessed the quality of outcome reporting according to the method used in other studies.^{8,9} There were six items; if the information of eligible studies completely meet the items, then 1 point was awarded. If this information did not meet or fully meet the items, then 0 point was awarded. If the outcome was objective, then the definition is unnecessary.

The items include the following:

1. Is the primary outcome clearly stated?
2. Is the primary outcome clearly defined so that another researcher would be able to reproduce its measurement? Where appropriate, this outcome should include a clear description of time points, the person measuring the outcome, how the outcome was measured (for example, tools and methods used) and where the outcome was measured.

Figure 3 The quality of outcome reporting in different types of clinical trials.

Figure 4 The quality of outcome reporting in different countries.

3. Are the secondary outcomes clearly stated?
4. Are the secondary outcomes clearly defined?
5. Do the authors explain the use of the outcomes they have selected?
6. Are methods used to enhance the quality of outcome measurement (for example, repeated measurement, training) if appropriate?

The methodological quality was assessed according to the type of study. The Jadad score was used to assess the quality of RCTs,¹⁰ and the Newcastle-Ottawa Scale was used to assess the quality of cohort studies (CoSs).¹¹ The tool developed by Canadian Institute of Health Economics can be used to assess the quality of case series studies.¹²

Two reviewers (RQ and JH) independently assessed the quality of outcome reporting and the methodological quality. Any disagreement was resolved by discussion or consulting the third investigator (HS).

Merging outcomes and grouping under outcome domains

Two researchers (RQ and CZ) merged the overlapping outcomes according to the definition of outcomes independently. If no definition was provided, they discussed and achieved consensus if necessary. For example, death, death from any cause, mortality, overall mortality, total mortality, all causes of death and all causes of mortality were aggregated as 'all-cause mortality'.

The original list of outcomes from systematic review is usually very long and unwieldy,¹³ so researchers developed a taxonomy for outcome classification¹⁴ that included 38 outcome domains. Two researchers (RQ and CZ) grouped individual outcomes into the appropriate outcome domain together and achieved consensus.

Statistical analysis

The results were analysed by descriptive analysis.

Patient and public involvement

Patients and the public were not involved in the design or planning of the study. Patients will be involved in the

larger study to develop the COS. Informed consent will be obtained from patients who will participate in the later research.

RESULTS

Characteristics of literature

In this systematic review, a total of 25 255 articles from Chinese and English databases were retrieved. After removing duplicates, there were 17 240 articles. By reading the titles and abstracts, ineligible articles were removed, and full texts for 1233 potential eligible articles were retrieved. A total of 1015 articles were removed for various reasons, and 218 articles were finally included. The flowchart of this systematic review is shown in figure 1.

In the included studies, 88 studies were for antiarrhythmic therapy, and 130 studies were for anticoagulant therapy. A total of 110 articles were in Chinese, and 108 articles were in English. Thirty articles were TCM clinical trials, and 188 were Western medicine clinical trials. Seventy-five articles were observational studies (including 66 CoS and 9 case series), while 143 articles were RCTs. The general characteristics of the included articles are shown in table 1.

The majority of RCTs were conducted in China. The USA had more CoSs than other countries did (figure 2). Because of the limited information provided in the articles, 35.32% (77/218) of the studies received 0 points for the quality of outcome reporting, and the majority were RCTs (figure 3). Compared with other countries, China had a much lower quality of outcome reporting (figure 4). The majority of RCTs were poor quality, while the majority of observational studies were high quality.

The list of outcomes

There are two main types of therapy for NVAf: antiarrhythmic treatment and anticoagulation treatment. Some differences exist in the outcome reporting between these

Table 2 The outcomes reporting for clinical trials of antiarrhythmic treatment (N=88)

Domains/outcomes	Outcomes reporting (n)	OMIs/ definitions (n)	Measurement time point (n)
Mortality/survival			
All-cause mortality	11	0	8
Cardiovascular death	5	0	3
Vascular outcomes			
Non-central nervous system embolism	6	0	2
Cardiac outcomes			
ECG outcomes	18	2	14
Time to conversion	7	1	5
Mean sinus rhythm maintenance time	1	1	6
Time to first AF recurrence	4	1	3
Conversion to sinus rhythm	26	1	12
Sinus rhythm maintenance	15	3	6
AF recurrence	36	2	2
AF progression	6	2	3
AF controlling rate	2	0	2
AF persistence	11	2	5
Number of electrical cardioversion	1	0	1
Number of taking antiarrhythmic drugs	1	0	1
Number of undertaking ablation	1	0	1
Ultrasonic cardiogram	39	1	10
Heart rate	21	2	14
NYHA classification grading of cardiac function	3	1	2
Myocardial infarction	2	0	2
Bradycardia	1	0	0
Ventricular arrhythmia	2	1	1
Heart failure	2	0	2
Blood pressure	20	0	6
NT-proBNP	3	0	3
Blood and lymphatic system outcomes			
D-dimer	2	0	2
APTT	1	0	1

Continued

Table 2 Continued

Domains/outcomes	Outcomes reporting (n)	OMIs/ definitions (n)	Measurement time point (n)
TT	1	0	1
PT	1	0	1
FIB	3	1	3
Nervous system outcomes			
Haemorrhagic stroke	11	0	6
Ischaemic stroke	6	0	4
Immune system outcomes			
IFN- γ	1	0	1
IL-10	1	0	1
IL-4	1	0	1
IL-6	10	1	4
TNF- α	9	1	4
MMP2	4	1	3
Solubility P-selectin	1	1	1
Connective tissue growth factor	1	1	1
TIMP2	1	1	1
Endocrine outcomes			
Aldosterone	1	0	1
ANP	1	1	1
TSH	2	0	1
Renin, AngII	4	1	1
Adiponectin	1	1	1
Hepatobiliary outcomes			
ALT	1	0	3
AST	1	0	3
Renal and urinary outcomes			
BUN	6	1	3
Serum creatinine	1	0	3
Urine sodium	1	0	1
Metabolism and nutrition outcomes			
HDL-C	3	0	4
LDL-C	7	1	4
TC	6	0	4
TG	5	0	4
Serum homocysteine	3	1	3
General outcomes			
Body mass index	1	0	1
Mean drug onset time	1	0	1
Symptoms	9	2	7
CRP	6	1	5
hs-CRP	12	2	4

Continued

Table 2 Continued

Domains/outcomes	Outcomes reporting (n)	OMIs/ definitions (n)	Measurement time point (n)
Adherence/compliance			
Therapeutic compliance	1	0	5
Withdrawal from treatment			
Withdrawal from treatment	1	0	1
Physical functioning			
6 Min walk test	1	1	1
Adverse events/effects			
Adverse events/ side effects	26	0	8
Resource use: Hospital			
All-cause hospitalisation	5	0	3
Cardiovascular hospitalisations	6	1	4
Hospital length of stay	1	0	0
Readmission rates	1	0	1

ALT, alanine aminotransferase; ANP, atrial natriuretic peptide; APTT, activated partial thromboplastin time; AST, aspartate aminotransferase; BUN, blood urea nitrogen; CRP, C reactive protein; ECG, electrocardiogram; FIB, fibrinogen; HDL-C, High density lipoprotein cholesterol; IFN- γ , interferon- γ ; IL, interleukin; LDL-C, low-density lipoprotein cholesterol; MMP2, matrix metalloproteinase-2; NT-proBNP, N terminal pro B type natriuretic peptide; NYHA, New York Heart Association; PT, prothrombin time; TC, total cholesterol; TG, total triglyceride; TIMP2, tissue inhibitor of metalloproteinase 2; TNF- α , tumour necrosis factor- α ; TSH, thyroid stimulating hormone; TT, thrombin time.

therapies. This review shows the outcomes according to the type of interventions in the original study.

For clinical trials of antiarrhythmic therapy, 69 outcomes from 16 outcome domains were reported (table 2). Twenty-eight (31.82%, 28/88) outcomes were reported only once; the most frequently reported outcome was ultrasonic cardiogram, which was reported 39 times (44.32%, 39/88). None of the outcomes were reported more than 50 times. In the 16 outcome domains, 5 outcome domains (vascular outcomes, adherence/compliance, adverse events/effects; physical functioning; withdrawal from treatment) consisted of only one outcome. These outcomes were reported between 1 and 26 times, and the median outcome reporting time was 1. Cardiac outcomes consisted of the largest number of outcomes, including 22 outcomes. In cardiac outcomes, ultrasonic cardiogram (39 times), AF recurrence (36 times), conversion to sinus rhythm (26 times), heart rate (21 times) and blood pressure (20 times) were reported much more often than other outcomes.

Table 3 The outcomes reporting for clinical trials of anticoagulant treatment (N=130)

Domains/outcomes	Outcomes reporting (n)	OMIs/ definitions (n)	Measurement time point (n)
Mortality/survival			
All-cause mortality	52	2	40
Cardiovascular death	26	2	13
Death from ischaemic events	3	0	1
Death from stroke	1	1	1
Death from bleeding	1	0	1
Non-cardiovascular death	1	0	1
Vascular outcomes			
Non-central nervous system embolism	73	1	31
Major bleeding	75	10	42
Time to first major bleeding event	2	0	3
Minor bleeding	21	2	8
Clinically relevant non-major bleeding	15	4	5
Time to first clinically relevant non-major bleeding event	1	0	2
Time to the first SEE	2	0	1
Cardiac outcomes			
Acute coronary syndrome	31	0	27
Ultrasonic cardiogram	1	1	1
Blood pressure	1	0	1
Heart failure	1	0	1
NT-proBNP	2	1	3
Blood and lymphatic system outcomes			
INR	17	1	7
Prothrombin time	8	1	5
APTT	8	1	5
PT	10	2	6
TT	5	1	5
FIB	4	1	3
Thrombin time	5	1	4
Time spent in the therapeutic range	5	0	3
PLT	2	0	2
RBC	1	0	1
HGB	1	0	1
D-dimer	3	0	3
Haemorheology	1	1	1
Thromboelastogram	1	1	1

Continued

Table 3 Continued

Domains/outcomes	Outcomes reporting (n)	OMIs/ definitions (n)	Measurement time point (n)
Plasma P selectin	1	1	1
TXB2	1	1	1
Nervous system outcomes			
Ischaemic stroke	105	2	56
Haemorrhagic stroke	75	2	39
Transient ischaemic attack	18	0	10
Intracranial bleeding	14	2	11
Time to the first stroke	3	0	2
Score standard of neural function deficient degree	1	1	1
Dementia	1	0	1
Hepatobiliary outcomes			
ALT	2	0	2
AST	2	0	2
TBIL	1	0	1
Renal and urinary outcomes			
Serum creatinine	1	1	1
Glomerular filtration rate	1	0	1
BUN	1	1	1
Creatinine clearance	1	0	1
Carbamide	1	0	1
β_2 -microglobulin	1	1	1
Musculoskeletal and connective tissue outcomes			
Hip fracture	2	0	1
Pelvic fracture	1	0	1
Vertebral fracture	1	0	1
General outcomes			
Symptoms	3	0	3
Warfarin dosage	2	0	1
INR variance growth rate	1	1	1
Time to stable anticoagulation	1	0	1
Weight	1	0	1
Traditional Chinese medicine syndrome	2	1	2
CRP	1	0	1
CGA score	1	1	2
Physical functioning			
Modified Rankin Scale score	1	1	1
Disability	1	0	1
Satisfaction/patient preference			
Patient satisfaction	3	3	4

Continued

Table 3 Continued

Domains/outcomes	Outcomes reporting (n)	OMIs/ definitions (n)	Measurement time point (n)
Adherence/compliance			
Therapeutic compliance	11	0	9
Anticoagulation discontinuation	3	1	8
Withdrawal from treatment			
Withdrawal from treatment	1	1	2
Global quality of life			
Quality of life	4	5	4
Economic			
Index hospitalisation costs	1	1	1
Resource use: Hospital			
Admission for cerebrovascular event	7	3	5
All-cause hospitalisation	4	0	2
Cardiovascular hospitalisation	4	0	1
Hospital length of stay	3	1	1
Bleeding-cause hospitalisation	2	0	3
Healthcare resource utilisation	2	1	1
Emergency room visits	1	0	10
Readmission rates	2	1	11
Need for further intervention			
The difference between the predicted and the actual warfarin maintenance dose	1	0	1
The number of warfarin dose changes needed	1	0	1
First catheter ablation	1	0	1
First AV node/His bundle ablation	1	0	1
Adverse events/effects			
Adverse events/ effects	16	0	7

ALT, alanine aminotransferase; APTT, activated partial thromboplastin time; AST, aspartate aminotransferase; AV, atrioventricular; BUN, blood urea nitrogen; CGA, comprehensive geriatric assessment; CRP, C reactive protein; FIB, fibrinogen; HGB, haemoglobin; INR, international normalised ratio; NT-proBNP, N terminal pro B type natriuretic peptide; PLT, platelet; PT, prothrombin time; RBC, red blood cell; SEE, systemic embolic event; TBIL, total bilirubin; TT, thrombin time; TXB2, thromboxane B2.

Figure 5 The summary of outcome reporting times.

For clinical trials of anticoagulation therapy, there were 82 outcomes from 18 outcome domains in the studies of anticoagulation therapy (table 3). Thirty-eight (29.23%, 38/130) outcomes were reported only once; the most frequently reported outcome was ischaemic stroke, which was reported 105 times (80.77%, 105/130). Only 5 (3.85%, 5/130) outcomes were reported more than 50 times. In the 18 outcome domains of anticoagulation therapy studies, 5 outcome domains (satisfaction/patient preference, withdrawal from treatment, global quality of life, economic and adverse events/effects) consisted of only one outcome. These outcomes were reported between 1 and 16 times, and the median outcome reporting time was 3. Blood and lymphatic system outcomes included the largest number of outcomes, which was 14 outcomes; the international normalised ratio (INR) was reported more frequently than other outcomes.

There were 24 duplicated outcomes between antiarrhythmic therapy and anticoagulation therapy. After removing duplicates, there were 127 outcomes. Figure 5

shows a summary of outcomes reporting times. Figure 6 shows the number of outcomes in different outcome domains in antiarrhythmic treatment trials. Figure 7 shows the number of outcomes in different outcome domains in anticoagulation treatment trials.

A large number of clinical trials did not provide definitions or OMIs. In the outcomes of antiarrhythmic treatment trials, 31 outcomes (44.93%, 31/69) were provided definitions or OMIs. Twenty-three (33.33%, 23/69) outcomes were provided one OMI or definition, seven (10.14%, 7/69) outcomes were provided two OMIs or definitions and one (1.45%, 1/69) outcome was provided three OMIs or definitions. Sinus rhythm maintenance had three different OMIs or definitions, which was higher than that of other outcomes. In the outcomes of anticoagulant therapy trials, 40 (48.78%, 40/82) were provided OMIs or definitions. Twenty-eight (35.37%, 28/82) outcomes were provided one OMI or definition, seven (8.54%, 7/82) outcomes were provided two OMIs or definitions and five (6.10%, 5/82) outcomes were provided

Figure 6 The number of outcomes in different outcome domains in antiarrhythmic treatment trials.

Figure 7 The number of outcomes in different outcome domains in anticoagulant treatment trials.

three or more OMIs or definitions. Major bleeding had more definitions than other outcomes did.

In addition, there were many different measurement times for the same outcome. In the clinical trials of antiarrhythmic treatment, the outcome measurement times ranged from 1 to 14 times, and the median time was 3. Forty-three outcomes (62.32%, 43/69) had two or more measurement times. Heart rate and ECG outcomes had more measurement times than other outcomes did. In clinical trials of anticoagulant therapy, the outcome measurement times ranged from 1 to 56, with a median of 1.5; among these outcomes 41 (50.00%, 41/82) had two or more measurement times. In addition, ischaemic stroke had more measurement times than other outcomes did.

DISCUSSION

This systematic review is the first to evaluate the quality of outcome reporting of clinical trials of TCM and western medicine for treating NVAf. The results showed variations in the outcome reporting, OMIs/outcome definitions and outcome measurement time reporting in different clinical trials. These problems may result in the exclusion of some studies from systematic reviews/meta-analyses due to the heterogeneity of outcomes or outcome measurements; thus, these studies cannot provide a higher level of evidence for clinical practice.

In clinical trials for NVAf, investment wastes also exist because approximately 1/3 of outcomes were reported only once in included trials of anticoagulation therapy and antiarrhythmic therapy. For example, conversion to sinus rhythm, which is important to the results of clinical trials of antiarrhythmic therapy, was reported by 29.55% (26/88) of articles. Some long-term outcomes, such as all-cause mortality and cardiovascular deaths, were reported in 12.50% (11/88) and 5.68% (5/88) of articles, respectively.

In addition, adverse events/effects were inadequately reported. In clinical trials of anticoagulant therapy, safety

outcomes such as haemorrhage were grouped under vascular outcomes according to the degree of bleeding (such as major bleeding, clinically relevant non-major bleeding and minor bleeding). Then, only 12.31% (16/130) of the included articles reported other kinds of adverse events/effects. For clinical trials of antiarrhythmic therapy, only 29.55% (26/88) of the included articles reported adverse events/effects.

For all of the outcomes in the list, patient' perspectives could not be identified sufficiently. For example, among all of the included 88 articles for antiarrhythmic therapy, none of them reported quality of life, while in all of the included 130 articles for anticoagulant therapy, only 4 of them reported quality of life.

There were 30 articles for clinical trials of TCM. TCM syndrome, which could reflect the characteristics of TCM, was reported only two times. A few other articles reported symptoms related to TCM syndrome. This phenomenon cannot reflect the characteristics and advantages of TCM.

After assessing the quality of outcome reporting and studies, the results showed that the majority of included trials had poor quality. Although the poor quality of studies may not influence the result of developing a long list of outcomes, the poor quality of outcome reporting made it difficult to extract sufficient information from the articles. The reasons for poor quality of studies and outcome reporting may be because most studies in China do not follow the Consolidated Standards of Reporting Trials (CONSORT) statement or observational studies reporting items. Moreover, the majority of journals in Chinese do not require studies to follow the CONSORT statement; thus, some studies provided limited information on key methodological issues. In addition, Chinese researchers prefer to report comprehensive outcomes rather than individual outcomes, and studies have reported only primary outcomes.

Only a small number of included studies provided OMIs or definitions, which made it difficult to assess

the quality of outcome measures. Additionally, the variation in OMI definitions can make it impossible to conduct meta-analyses. In addition, selecting OMIs with good measurement properties is very important after developing a COS¹⁵ to ensure that reliability, validity and ethical standards are achieved.

The measurement time was much shorter in Chinese journals than in English journals. In general, long-term outcomes were usually reported in observational studies, while short-term outcomes were usually reported in RCTs. It is a challenge for a single trial to measure all of these outcomes in a meaningful way, especially an outcome such as mortality, which requires longer follow-up and a larger sample size.¹⁶ Therefore, recommending measurement times for different outcomes is important.

Developing a COS for NVAf may reduce the heterogeneity of outcome reporting in different clinical trials, so that clinical trials can be included in systematic reviews/meta-analyses to provide a higher quality of evidence for clinical practice. Moreover, if the majority of clinical trials can be included in systematic review, it may help reduce investment wastes. Reviewers can easily determine if publication bias is present when a COS is used. For TCM clinical trials, a COS may help improve the quality of studies if researchers report consensus outcomes, which may help improve the development of TCM.

Author affiliations

¹Key Laboratory of Chinese Internal Medicine of Ministry of Education and Beijing, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China

²Baokang Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China

³Evidence-based Medicine Center, Jiangxi University of Chinese Medicine, Nanchang, China

Contributors RQ, JC and HS contributed to the study design. RQ extracted data from articles and drafted the manuscript. SH, YH, TH, CZ and JH contributed to the data extracting and assessment. ML, JH, JC, YL, MG and HS revised the manuscript. All authors read and approved the final manuscript.

Funding This work was supported by the National Natural Science Foundation of China [81430098].

Competing interests None declared.

Patient consent for publication Not required.

Ethics approval Ethical approval has been granted by the Ethics Committee of Dongzhimen Hospital, Beijing University of Chinese Medicine (DZMEC-KY-2017-81).

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement The data are from published papers and do not include identifiable patient data.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

REFERENCES

- Odutayo A, Wong CX, Hsiao AJ, *et al*. Atrial fibrillation and risks of cardiovascular disease, renal disease, and death: systematic review and meta-analysis. *BMJ* 2016;354.
- January CT, Wann LS, Alpert JS, *et al*. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American heart association Task force on practice guidelines and the heart rhythm Society. *J Am Coll Cardiol* 2014;64:e1-76.
- Kirchhof P, Benussi S, Kotecha D, *et al*. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. *Rev Esp Cardiol* 2017;70.
- Heart Rhythm Society of the Chinese Society of Biomedical Engineering, Nao Xin Tong Zhi Committee of the Chinese Association of Integrative Medicine. Expert consensus on Wenxin granule for treatment of cardiac arrhythmias. *Chin Med J* 2017;130:203-10.
- COMET Initiative. Available: <http://www.comet-initiative.org/> [Accessed 1 Apr 2019].
- Shang H, Qiu R, Zhang X, *et al*. A core outcome set for clinical trials of traditional Chinese medicine in non-valvular atrial fibrillation. Available: <http://www.comet-initiative.org/studies/details/941> [Accessed 1 Apr 2019].
- Qiu R, Li M, Zhang X, *et al*. Development of a core outcome set (COS) and selecting outcome measurement instruments (OMIs) for non-valvular atrial fibrillation in traditional Chinese medicine clinical trials: study protocol. *Trials* 2018;19:541.
- Durnea CM, Pergialiotis V, Duffy JMN, *et al*. A systematic review of outcome and outcome-measure reporting in randomised trials evaluating surgical interventions for anterior-compartment vaginal prolapse: a call to action to develop a core outcome set. *Int Urogynecol J* 2018;29:1727-45.
- Alkhaffaf B, Blazeby JM, Williamson PR, *et al*. Reporting of outcomes in gastric cancer surgery trials: a systematic review. *BMJ Open* 2018;8:e21796.
- Jadad AR, Moore RA, Carroll D, *et al*. Assessing the quality of reports of randomized clinical trials: is blinding necessary? *Control Clin Trials* 1996;17:1-12.
- Wells G, Shea B, O'Connell D, *et al*. The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp [Accessed 1 Apr 2019].
- Moga C, Guo B, Schopflocher D. Development of a quality appraisal tool for case series studies using a modified Delphi technique. Edmonton AB: Institute of Health Economics, 2012. <https://www.ihe.ca/research-programs/rmd/cssqac/cssqac-info> [Accessed 1 Apr 2019].
- Hopkins JC, Howes N, Chalmers K, *et al*. Outcome reporting in bariatric surgery: an in-depth analysis to inform the development of a core outcome set, the BARIAct study. *Obes Rev* 2015;16:88-106.
- Dodd S, Clarke M, Becker L, *et al*. A taxonomy has been developed for outcomes in medical research to help improve knowledge discovery. *J Clin Epidemiol* 2018;96:84-92.
- Prinsen CAC, Vohra S, Rose MR, *et al*. How to select outcome measurement instruments for outcomes included in a "Core Outcome Set" - a practical guideline. *Trials* 2016;17:449.
- Marcum ZA, Steinman MA. Developing a core outcome set for trials to improve medication use: guidelines or guidance? *J Am Geriatr Soc* 2018;66:1058-9.
- Kang DW. Antithrombotic therapy for coronary heart disease complicated with atrial fibrillation [In Chinese]. *Gansu Med J* 2015;34:118-20.
- Guo SG, Guo JR, Xu HL, *et al*. Effect of atorvastatin on the prognosis in patients with coronary heart disease complicated with chronic heart failure and atrial fibrillation [In Chinese]. *Hainan Med J* 2015;26:486-9.
- Li L, Luo XL, Wang HY. Analysis on efficacy and safety of amiodarone combined with dabigatran etexilate in treatment of non-valvular atrial fibrillation [In Chinese]. *Lab Med Clin* 2015;12:1997-8.
- Bu QF, Jiao DL, LiFX. Effectivity and safety of low-intensity warfarin anticoagulation in elderly patients with nonvascular atrial fibrillation [In Chinese]. *Clin J Med Off* 2015;43:969-70.
- Pan XM, Liu S. Effects of candesartan and rosuvastatin on the left atrial structure of patients with atrial fibrillation [In Chinese]. *Chinese Baby* 2016;9:11-12.
- Li D. Effect of dabigatran on coagulation function in elderly patients with non-valvular atrial fibrillation [In Chinese]. *Shandong Med J* 2015;55:65-6.
- Chen J, Hong HS, Zhou YW. Study on Application of Warfarin in Treatment of Non Valvular Atrial Fibrillation Anticoagulation [In Chinese]. *China Contin Med Educ* 2015;7:117-9.
- Sang J, Sui LJ, Gao CZ. Effects of valsartan combined with rosuvastatin on plasma levels of C-reactive protein, tumor necrosis factor- α and interleukin-6 in elderly patients with

- permanent atrial fibrillation [In Chinese]. *Chin J Gerontol* 2015;35:2025–7.
25. Guo LP. Efficacy of amiodarone combined with irbesartan in the prevention of atrial fibrillation. *Chin Pract Med* 2015;10:152–3.
 26. Zuo J, Gao Y, Hua Y, et al. Evaluation on the efficacy and safety of pradax on non - valvular atrial fibrillation anticoagulation therapy in 90 cases [In Chinese]. *China Pharmaceuticals* 2015;24:42–3.
 27. Liu YH, Li HY, Zhang SL, et al. Clinical observation of dabigatran etexilate in anticoagulant therapy for non-valvular atrial fibrillation [In Chinese]. *Cardiovasc Dis J Int Tradit Chin Western Med* 2016;4:3–4.
 28. Yang D. Therapeutic effect of amlodipine on patients with hypertension complicated with atrial fibrillation [In Chinese]. *For All Health* 2015;9:145–6.
 29. Li HW, Li J, Tao J. Clinical observation of patients with hypertension combined with persistent atrial fibrillation in the treatment of candesartan combined with amiodarone [In Chinese]. *Med Inform* 2015;28:30–1.
 30. Yang XB, Wang MY, Zhang YJ, et al. Clinical observation of sotalol combined with irbesartan in patients with hypertension complicated with paroxysmal atrial fibrillation [In Chinese]. *Chin J Prim Med Pharm* 2015;22:123–4.
 31. Li GH, Lai YW, Yang YP. Clinical trial of effect of valsartan on inflammatory factors in patients with hypertension complicated with persistent atrial fibrillation [In Chinese]. *Chin J Mod Drug Appl* 2015;9:89–90.
 32. Lin W, Yu DH, Li ZY. Therapeutic effect of rosuvastatin on elderly patients with chronic heart failure complicated with atrial fibrillation [In Chinese]. *Chin J Mod Drug Appl* 2015;9:127–8.
 33. Qin PY, Xuan CX, Zhou Q. Therapeutic effect of proper doses of warfarin on prevention of ischemic stroke in patients of different ages with non-valvular atrial fibrillation [In Chinese]. *J Guangxi Med Univ* 2016;33:691–3.
 34. Qin PY, Zhou Q, Xuan CX. Observation of efficiency and safety of different dosages of warfarin in prevention of thromboembolism in young and middle-aged patients with nonvalvular atrial fibrillation [In Chinese]. *Psychol Doct* 2016;22:30–1.
 35. Chen L, Xu J, Ren Q, et al. The curative effect observation of dabigatran etexilate combined with dual antiplatelet for antithrombotic therapy after percutaneous coronary intervention of non-valvular atrial fibrillation for atrial fibrillation [In Chinese]. *Shaanxi Med J* 2016;45:758–9.
 36. Wang WM, Peng BT, Chen J, et al. The effect of anti-platelet and anticoagulant therapy on preventing ischemic stroke in patients with non-valvular atrial fibrillation [In Chinese]. *Chin J Mod Drug Appl* 2015;9:169–71.
 37. Liu JX, Zhang X. Effect of different dosage of warfarin on the incidence of hemorrhage and D-dimer concentration in patients with non-valvular atrial fibrillation [In Chinese]. *Cardiovasc Dis J Int Tradit Chin West Med* 2015;3:85–6.
 38. Zhang RH. Clinical efficacy and safety evaluation of irbesartan in the treatment of atrial fibrillation [In Chinese]. *Contemp Med* 2015;21:124–5.
 39. Zhang YT. Clinical observation of amiodarone in treatment of acute myocardial infarction complicated with atrial fibrillation [In Chinese]. *China & Foreign Med Treat* 2015;14:101–2.
 40. Huang ZX, Xie CL, He ZW. Clinical study on irbesartan combined ammonia amiodarone in treatment of non-valvular paroxysmal atrial fibrillation [In Chinese]. *Med Innov China* 2015;12:57–9.
 41. Xu X, Wang B, Chen S. Clinical observation of antithrombotic effect of warfarin and aspirin in elderly patients with paroxysmal atrial fibrillation [In Chinese]. *Chin J Int Med Cardio Cerebrovasc Dis* 2015;13:118–9.
 42. Lin X. Clinical efficacy of candesartan combined with amiodarone in the treatment of elderly patients with hypertension complicated with persistent atrial fibrillation [In Chinese]. *Chin J Gerontol* 2015;35:6754–6.
 43. Zhang Z, Zong YQ. The effect of different dosage of warfarin in treatment of elderly patients with stable coronary heart disease and combined atrial fibrillation. *Cardiovascular Disease* [In Chinese]. *J Int Tradit Chin West Med* 2016;4:1–2.
 44. Guo WD. Clinical efficacy of amiodarone combined with irbesartan in the treatment of paroxysmal atrial fibrillation [In Chinese]. *Chin J Clin Ration Drug Use* 2015;8:31–2.
 45. Zhang JS. Clinical efficacy and safety of valsartan and indapamide in the treatment of paroxysmal atrial fibrillation [In Chinese]. *J Med Forum* 2015;36:158–9.
 46. Yang ZQ, Yao XL. Efficacy Observation of Bisoprolol with Methimazole Treatment of Elderly Patients with Subclinical Hyperthyroidism and Atrial Fibrillation [In Chinese]. *Mod Diagn Treat* 2015;26:801–2.
 47. Zhang RS, Gu X. Efficiency of intravenous amiodarone in congestive heart failure patients with atrial fibrillation [In Chinese]. *Chin J Mult Organ Dis Elder* 2015;14:454–7.
 48. Hou L, Liu MY. Clinical observation of amiodarone combined with irbesartan in the treatment of 136 patients with paroxysmal atrial fibrillation [In Chinese]. *Psychol Doct* 2015;21:50–1.
 49. Jiang YC, Xu B. Effect of amiodarone plus valsartan treatment in senile patients With persistent atrial fibrillation [In Chinese]. *Tianjin Pharm* 2016;28:28–30.
 50. Song CY, Lv LF, Zhong Y. Effect of amiodarone combined with foscipril on the efficacy of electrocardiogram in patients with atrial fibrillation [In Chinese]. *World Latest Med Inform* 2015;15.
 51. Wang Q, Yuan W. Evaluation of the therapeutic effect of bisoprolol on heart failure patients with persistent atrial fibrillation [In Chinese]. *Med Inform* 2015;28:26–7.
 52. Yan HF, Huang XY, Cai JF. Treatment of elderly patients with AMI and AF by Propafenone and Amiodarone and analysis the efficacy and adverse reactions [In Chinese]. *J China Prescription Drug* 2015;13:12–13.
 53. Zhang Y, Yin SN. Clinical efficacy of amiodarone combined with irbesartan in the treatment of patients with hypertension complicated with paroxysmal atrial fibrillation. *Chin J Integr Med Cardio Cerebrovasc Dis* 2015;13:534–5.
 54. Jian JQ. The efficacy and safety of warfarin in the treatment of atrial fibrillation [In Chinese]. *Health Guide* 2017;16.
 55. Huang HW, Qin XX. Clinical observation of dabigatran etexilate in prophylactic anticoagulation of elderly nonvalvular atrial fibrillation: 30 cases [In Chinese]. *J Guangdong Med Coll* 2016;34:282–4.
 56. Yang HX. Effect of rosuvastatin on hypertension and paroxysmal atrial fibrillation [In Chinese]. *Psychol Doct* 2017;23:7–8.
 57. Liu XB, Huang HM, Feng LL, et al. Different intensity warfarin anticoagulation therapy for elderly stable coronary heart disease patients with atrial fibrillation [In Chinese]. *Chin J Geriatr Heart Brain Vessel Dis* 2016;18:132–5.
 58. Zhou L, Tang L, Xing X, et al. Effects of different doses of atorvastatin on high-sensitivity C-reactive protein, interleukin-6, tumor necrosis factor- α , adiponectin levels in elderly patients with coronary heart disease complicated with atrial fibrillation [In Chinese]. *Chin J Gerontol* 2016;36:2892–3.
 59. Chen J. Clinic Effects of Amiodarone combining enalapril in treatment of patients with hypertension and paroxysmal atrial fibrillation [In Chinese]. *Med Recapitulate* 2016;22:1812–5.
 60. Wang XM, Jin L. Effect of strengthen rosuvastatin in the treatment of patients with paroxysmal atrial fibrillation in coronary artery disease and the influence on serum inflammatory factor [In Chinese]. *Chin J Prim Med Pharm* 2016;23:961–4.
 61. Ou Y. Application effect and mechanism analysis of atorvastatin in the treatment of elderly patients with coronary heart disease and atrial fibrillation [In Chinese]. *Chin Commun Doct* 2017;33:17–18.
 62. Geng QF, Liu YH, Li HY, et al. The efficacy of aspirin combined with dipyridamole in patients with non-valvular atrial fibrillation [In Chinese]. *Cardiovasc Dis J Integr Tradit Chin West Med* 2016;4:1–2.
 63. Chu YZ. Clinical efficacy and safety of amiodarone and benazepril in the treatment of paroxysmal atrial fibrillation [In Chinese]. *Chin J Pract Med* 2017;44:18–20.
 64. Zhu Y. Efficacy of candesartan combined with amiodarone in elderly patients with hypertension complicated with persistent atrial fibrillation [In Chinese]. *Chin J Med Device* 2017;30:17–18.
 65. Lin S. Efficacy of telmisartan combined with amiodarone in the patients with hypertension complicated with paroxysmal atrial fibrillation and influence on the levels of serum BNP, MMP-2 and CTGF [In Chinese]. *China Pharm* 2017;20:1055–8.
 66. Duan WT, Shi D, Wang XD, et al. The effect of maintaining sinus rhythm of amiodarone combined in patients with persistent atrial fibrillation [In Chinese]. *Chin J Gerontol* 2017;37:1924–5.
 67. Lu Y, Wen LA, Li D, et al. Clinical observation of dabigatran and warfarin in treating nonvalvular atrial fibrillation [In Chinese]. *China Pharm* 2017;26:49–51.
 68. Wei ZY, Lin YP. Compared the efficacy and safety of dabigatran with warfarin in the treatment of atrial fibrillation complicated with chronic kidney disease. *Chin Prev Med* 2016;17:947–50.
 69. Su Q, Cheng J, Deng XF, et al. Clinical study of amiodarone in the treatment of elderly patients with acute myocardial infarction complicated with atrial fibrillation [In Chinese]. *Prog Mod Biomed* 2017;17:856–8.
 70. Yu HY. The efficacy of amiodarone combined with irbesartan in patients with hypertension complicated with paroxysmal atrial fibrillation [In Chinese]. *Med J Chin People Health* 2016;28:27–8.
 71. Li XY, Huang J, Dai J. The efficacy of perindopril combined with atorvastatin on inflammatory factors in patients with hypertension

- complicated with paroxysmal atrial fibrillation [In Chinese]. *Jiangsu Med J* 2016;42:2720–2.
72. Wen H. Clinical study of different doses of aspirin in preventing thrombosis in patients with atrial fibrillation [In Chinese]. *Heilongjiang Med Pharm* 2016;39:57–8.
 73. Chen YL. Antithrombotic effect of different doses of warfarin in elderly patients with paroxysmal atrial fibrillation [In Chinese]. *J Bethune Mil Med Coll* 2016;14:71–2.
 74. Xu ZT, Feng ZX, Wang Q, et al. Compared the therapeutic effect of metoprolol combined with spironolactone with metoprolol combined with valsartan in the treatment of isolated paroxysmal atrial fibrillation [In Chinese]. *Prev Treat Cardio Cerebral Vasc Dis* 2016;16:48–50.
 75. Huang H, He XQ, Zhang HM, et al. Effects of rosuvastatin on hypertension with paroxysmal atrial fibrillation [In Chinese]. *J Trop Med* 2016;16:1132–6.
 76. Zhao TB, Dong XH. Effect of atorvastatin calcium on elderly patients with chronic heart failure complicated with atrial fibrillation [In Chinese]. *China Prescription Drug* 2017;15.
 77. Feng WJ, Zhang R, Li LL, et al. Therapeutic effect and safety of combined therapy of Maixuekang capsule and low-intensity-anticoagulation warfarin with aspirin on acute cerebral infarction in elderly patients with non-valvular atrial fibrillation [In Chinese]. *Hebei Med J* 2015;37:663–5.
 78. Bo YL, Li WZ, Pan XM. Clinical observation of the effect of amiodarone combined with wenxin granules on conversion and maintenance of sinus rhythm in 80 patients with atrial fibrillation [In Chinese]. *Chin J Ethnomed Ethnopharm* 2015;24:53–4.
 79. Zhang BG, Peng ZX. Clinical observation of buyanghuanwu decoction in treatment of chronic heart failure with rapid atrial fibrillation [In Chinese]. *Hubei J Tradit Chin Med* 2016;38:1–3.
 80. Chen YY, Yan ZQ, He XP, et al. Effect of Jianxin Pinglu Pill on MMP 2 and TIMP 2 in patients with persistent atrial fibrillation [In Chinese]. *Chin J Integr Med Cardio Cerebrovasc Dis* 2016;14:1194–6.
 81. Cao WZ, Zhong DC, Shi ZY, et al. Clinical efficacy and influence of Shensongyangxin capsule on inflammatory factors in patients with atrial fibrillation [In Chinese]. *Chin J Diff Complicat Cases* 2015;14:387–90.
 82. Chang GD, Zhou YT. Clinical observation of atorvastatin combined with wenxin granules in the treatment of paroxysmal atrial fibrillation [In Chinese]. *Med Innov China* 2015;12:63–4.
 83. Fan XJ. Efficacy of losartan combined with amiodarone and Shensong Yangxin capsule in the treatment of hypertension with paroxysmal atrial fibrillation [In Chinese]. *For All Health* 2015;9.
 84. Ye LJ. Clinical observation of the therapeutic effect of Wenxin granule combined with propafenone in patients with atrial fibrillation [In Chinese]. *Cardiovas Dis J Integr Tradit Chin West Med* 2016;4:68–9.
 85. Wang TX. To observe the curative effect of Taoren Honghua decoction combined with warfarin in the treatment of non valvular atrial fibrillation and blood stasis [In Chinese]. *Cardiovas Dis J Integr Tradit Chin West Med* 2015;3:30–2.
 86. Cheng J, Zhang DC, Fan LL, et al. Clinical Research of Yangxin Guicao Tang in Patients with Persistent or Permanent Atrial Fibrillation [In Chinese]. *Liaon J Tradit Chin Med* 2015;42:1254–6.
 87. Han J, Deng Y, Chen JC, et al. The efficacy of Xifeng Zhizhi Decoction in treating 30 patients with paroxysmal atrial fibrillation [In Chinese]. *Glob Tradit Chin Med* 2015;8:602–4.
 88. Peng XG. Effect of Shexiang Baixin pills combined with amiodarone on heart rate, blood pressure and atrial fibrillation in patients with hypertensive heart disease complicated with atrial fibrillation [In Chinese]. *J New Chin Med* 2015;47:16–17.
 89. Zhang ML. Effect of Buchang Wenxin Granule in the treatment of elderly patients with diastolic heart failure and paroxysmal atrial fibrillation [In Chinese]. *Chin J Pract Med* 2015;42:69–70.
 90. Pan TS, Yan ZQ, Chen YY, et al. Clinical observation of Jianxin Pinglu pill combined with amiodarone in the treatment of paroxysmal atrial fibrillation [In Chinese]. *J New Chin Med* 2016;48:14–15.
 91. Huang SS. Clinical efficacy of valsartan combined with Dabuyuanjian on elderly patients with paroxysmal atrial fibrillation [In Chinese]. *Clin Med* 2016;36:11–12.
 92. Li FN, Kuang P, Chen Y, et al. Effect of Shensongyangxin capsules combined with amiodarone on MMP-2 and hs-CRP of patients with paroxysmal atrial fibrillation [In Chinese]. *Intern Med China* 2016;11:694–7.
 93. Wang LN, Wang XF. Effect of the Wenxin granules on inflammatory cytokines of patients with permanent atrial fibrillation [In Chinese]. *Chin J Pract Med* 2016;43:123–5.
 94. Cui XT. Effect of Zhigancao decoction combined with metoprolol on ventricular rate and plasma Hcy level in patients with chronic atrial fibrillation [In Chinese]. *Mod J Integr Tradit Chin West Med* 2017;26:162–3.
 95. Bi MH. Effect of Dingxin granule on early blood pressure in patients with hypertension complicated with paroxysmal atrial fibrillation [In Chinese]. *Chin Foreign Med Res* 2016;14:110–1.
 96. Zhang XS. Efficacy observation of sotalol combined with shensong yangxin capsule in the treatment of coronary heart disease with rapid atrial fibrillation [In Chinese]. *Med Innov China* 2017;14:99–102.
 97. Chen T, Chang ZL, Fan XH, et al. Effect of Zhigancao decoction combined with amiodarone on paroxysmal atrial fibrillation and atrial remodeling [In Chinese]. *China Mod Doct* 2017;55:118–21.
 98. Liu J, Liao Y, Tang Y. Effect of Dingxin granules combined with metoprolol on P wave dispersion and serum inflammatory factors in patients with paroxysmal atrial fibrillation [In Chinese]. *Mod J Integr Tradit Chin West Med* 2017;26:2564–6.
 99. Zhang RZ. Curative effect observation of Wenxin Granule combined with amiodarone in treating 84 cases of paroxysmal atrial fibrillation [In Chinese]. *Clin J Chin Med* 2016;8:37–8.
 100. Granger CB, Lopes RD, Hanna M, et al. Clinical events after transitioning from apixaban versus warfarin to warfarin at the end of the apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) trial. *Am Heart J* 2015;169:25–30.
 101. Held C, Hylek EM, Alexander JH, et al. Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial. *Eur Heart J* 2015;36:1264–72.
 102. Jaspers Focks J, Brouwer MA, Wojdyla DM, et al. Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: post hoc analysis of the ARISTOTLE trial. *BMJ* 2016;353.
 103. Bahit MC, Lopes RD, Wojdyla DM, et al. Non-major bleeding with apixaban versus warfarin in patients with atrial fibrillation. *Heart* 2017;103:623–8.
 104. Alexander JH, Andersson U, Lopes RD, et al. Apixaban 5 Mg twice daily and clinical outcomes in patients with atrial fibrillation and advanced age, low body weight, or high creatinine: a secondary analysis of a randomized clinical trial. *JAMA Cardiol* 2016;1:673–81.
 105. Hu PT, Lopes RD, Stevens SR, et al. Efficacy and safety of apixaban compared with warfarin in patients with atrial fibrillation and peripheral artery disease: insights from the ARISTOTLE trial. *J Am Heart Assoc* 2017;6:e004699.
 106. Pengo V, Zamboni C-F, Fogar P, et al. A randomized trial of pharmacogenetic warfarin dosing in naïve patients with Non-Valvular atrial fibrillation. *PLoS One* 2015;10:e0145318.
 107. Steffel J, Giugliano RP, Braunwald E, et al. Edoxaban vs. warfarin in patients with atrial fibrillation on amiodarone: a subgroup analysis of the engage AF-TIMI 48 trial. *Eur Heart J* 2015;36:2239–45.
 108. Yamashita T, Koretsune Y, Yang Y, et al. Edoxaban vs. Warfarin in East Asian patients with atrial fibrillation- An ENGAGE AF-TIMI 48 subanalysis. *Circ J* 2016;80:860–9.
 109. Kato ET, Giugliano RP, Ruff CT, et al. Efficacy and safety of edoxaban in elderly patients with atrial fibrillation in the engage AF-TIMI 48 trial. *J Am Heart Assoc* 2016;5:e003432.
 110. Meng Z, Tan J, He Q, et al. Wenxin keli versus sotalol for paroxysmal atrial fibrillation caused by hyperthyroidism: a prospective, open label, and randomized study. *Evid Based Complement Altern Med* 2015;2015:1–9.
 111. Wang H, Zhou X-K, Zheng L-F, et al. Comparison of aspirin and Naointong capsule () with adjusted-dose warfarin in elderly patients with high-risk of non-valvular atrial fibrillation and genetic variants of vitamin K epoxide reductase. *Chin J Integr Med* 2018;24:247–53.
 112. Brambatti M, Darius H, Oldgren J, et al. Comparison of dabigatran versus warfarin in diabetic patients with atrial fibrillation: results from the RE-LY trial. *Int J Cardiol* 2015;196:127–31.
 113. Verdecchia P, Reboldi G, Angeli F, et al. Dabigatran vs. warfarin in relation to the presence of left ventricular hypertrophy in patients with atrial fibrillation- the randomized evaluation of long-term anticoagulation therapy (RE-LY) study. *Europace* 2018;20:253–62.
 114. Tan Q, Zhang S, Zou X, et al. Fluvastatin therapy could not decrease progression of paroxysmal atrial fibrillation in non-valvular disease patients. *Anatol J Cardiol* 2017;18:103–7.
 115. Shah R, Hellkamp A, Lokhnygina Y, et al. Use of concomitant aspirin in patients with atrial fibrillation: findings from the rocket AF trial. *Am Heart J* 2016;179:77–86.
 116. Sun Y, Hu D, Stevens S, et al. Efficacy and safety of rivaroxaban versus warfarin in patients from mainland China with nonvalvular

- atrial fibrillation: a subgroup analysis from the rocket AF trial. *Thromb Res* 2017;156:184–90.
117. Yao H, Jiang L, Lin X, *et al.* Fluvastatin combined with benazepril may contribute to the favorable prognosis of patients with atrial fibrillation. *Biomed Pharmacother* 2016;83:687–92.
 118. Goette A, Merino JL, Ezekowitz MD, *et al.* Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3B trial. *Lancet* 2016;388:1995–2003.
 119. Magnani G, Giugliano RP, Ruff CT, *et al.* Efficacy and safety of edoxaban compared with warfarin in patients with atrial fibrillation and heart failure: insights from engage AF-TIMI 48. *Eur J Heart Fail* 2016;18:1153–61.
 120. Senoo K, Lip GYH, Lane DA, *et al.* Residual risk of stroke and death in anticoagulated patients according to the type of atrial fibrillation. *Stroke* 2015;46:2523–8.
 121. Hijazi Z, Hohnloser SH, Andersson U, *et al.* Efficacy and safety of apixaban compared with warfarin in patients with atrial fibrillation in relation to renal function over time. *JAMA Cardiol* 2016;1:451–60.
 122. Cadrin-Tourigny J, Shohoudi A, Roy D, *et al.* Decreased mortality with beta-blockers in patients with heart failure and coexisting atrial fibrillation an AF-CHF substudy. *JACC Heart Fail* 2017;5:99–106.
 123. Maciag A, Farkowski MM, Chwyczko T, *et al.* Efficacy and safety of antazoline in the rapid cardioversion of paroxysmal atrial fibrillation (the AnPAF study). *Europace* 2017;19:1637–42.
 124. Ng KH, Shestakovska O, Connolly SJ, *et al.* Efficacy and safety of apixaban compared with aspirin in the elderly: a subgroup analysis from the AVERROES trial. *Age Ageing* 2016;45:77–83.
 125. Inoue H, Atarashi H, Okumura K, *et al.* Heart rate control by carvedilol in Japanese patients with chronic atrial fibrillation: the AF carvedilol study. *J Cardiol* 2017;69:293–301.
 126. Dong Z, Yao H, Miao Z, *et al.* Pretreatment with intravenous amiodarone improves the efficacy of ibutilide treatment on cardioversion rate and maintenance time of sinus rhythm in patients with persistent atrial fibrillation. *Biomed Rep* 2017;6:686–90.
 127. Hong K-S, Kwon SU, Lee SH, *et al.* Rivaroxaban vs warfarin sodium in the ultra-early period after atrial fibrillation-related mild ischemic stroke: a randomized clinical trial. *JAMA Neurol* 2017;74:1206–15.
 128. Tan Q, Li GP, Zhang SY, *et al.* Effect of fluvastatin on preventing the recurrence of paroxysmal atrial fibrillation [In Chinese]. *J Chin Pract Diagn Ther* 2017;31:384–6.
 129. Zhang YQ, Yin XR. Effects of different doses of rosuvastatin in patients with paroxysmal atrial fibrillation [In Chinese]. *Pract Geriatr* 2016;30:994–6.
 130. Zhou H, Wang ZJ, Zhou MF, *et al.* Clinical research of telmisartan in preventing hypertension with paroxysmal atrial fibrillation [In Chinese]. *Chin J Prim Med Pharm* 2016;23:3696–700.
 131. Qian CS, Sun Y, Sheng CH, *et al.* Clinical observation of Yiqi Yangyin in treating DHF complicated with atrial fibrillation [In Chinese]. *Zhejiang Clin Med J* 2017;19:662–4.
 132. Di Y, Wang ZJ, Zha WH, *et al.* Effect of telmisartan on recurrence of paroxysmal atrial fibrillation in patients with hypertension and cardiac dysfunction [In Chinese]. *J Clin Intern Med* 2017;34:316–9.
 133. Liu ZY. Clinical efficacy of valsartan in the treatment of hypertension complicated with atrial fibrillation [In Chinese]. *Chin J Integr Med Cardio Cerebrovas Dis* 2017;15:1374–6.
 134. Yu M, Yu AQ, Yu DJ. Influence of rosuvastatin combined with valsartan in C reactive protein and myocardium remodeling in patients with hypertension complicated with paroxysmal atrial fibrillation [In Chinese]. *Chin J Lab Diagn* 2017;21:1141–4.
 135. Zhang J, Jiao WW. Research advances of new oral anticoagulants in the prevention of stroke in patients with non-valvular atrial fibrillation [In Chinese]. *J Int Neurol Neurosurg* 2015;42:538–41.
 136. Li J, Zhou Q, Ma L, *et al.* Effect of telmisartan on hypertension patients with paroxysmal atrial fibrillation [In Chinese]. *Guangxi Med J* 2015;37:614–6.
 137. Pang F, Gong YX, Zheng GM. Clinical observation of valsartan in the treatment of hypertension complicated with atrial fibrillation [In Chinese]. *Sci Technol Vis* 2015;349.
 138. Wang B. Clinical observation on efficacy of irbesartan combined with atorvastatin in treatment of hypertension complicated with paroxysmal atrial fibrillation [In Chinese]. *Med Recapitulate* 2015;21:3972–4.
 139. Yan Y, Zhang B, Wang XG, *et al.* Clinical effect of benazepril combined with amiodarone in patients with paroxysmal atrial fibrillation. *China J Pharm Econ* 2015;12:38–9.
 140. Huang JZ, Peng J, Gao SL. The effects of valsartan on levels of inflammatory factors and left atrial diameter in the elderly patients with hypertension complicated persistent atrial fibrillation [In Chinese]. *Prev Treat Cardio Cerebral Vasc Dis* 2015;15:107–9.
 141. Yuan S, Liu FS. Effects of cotherapy with candesartan cilexetil and rosuvastatin on patients with chronic cardiac insufficiency and paroxysmal atrial fibrillation [In Chinese]. *J Precision Med* 2015;30:587–9.
 142. Chen JK, Zhu PL, Yan Y, *et al.* Small doses of rivaroxaba prevents stroke in advance-aged type 2 diabetics with atrial fibrillation [In Chinese]. *J China Med Univ* 2015;44:755–7.
 143. Tu HY. Efficacy and safety of warfarin in the treatment of elderly patients with non-valvular atrial fibrillation [In Chinese]. *Guide China Med* 2016;14:140–1.
 144. Bassand J-P, Accetta G, Camm AJ, *et al.* Two-Year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF. *Eur Heart J* 2016;37:2882–9.
 145. Haas S, ten Cate H, Accetta G, *et al.* Quality of vitamin K antagonist control and 1-year outcomes in patients with atrial fibrillation: a global perspective from the GARFIELD-AF registry. *PLoS One* 2016;11:e0164076.
 146. Chan P-H, Huang D, Hai JJ, *et al.* Stroke prevention using dabigatran in elderly Chinese patients with atrial fibrillation. *Heart Rhythm* 2016;13:366–73.
 147. Chan P-H, Huang D, Lau C-P, *et al.* Net clinical benefit of dabigatran over warfarin in patients with atrial fibrillation stratified by CHA2DS2-VASc and time in therapeutic range. *Can J Cardiol* 2016;32:1247.e15–1247.e21.
 148. Xie L, Vo L, Keshishian A, *et al.* Comparison of hospital length of stay and hospitalization costs among patients with non-valvular atrial fibrillation treated with apixaban or warfarin: an early view. *J Med Econ* 2016;19:769–76.
 149. Bengtson LGS, Lutsey PL, Chen LY, *et al.* Comparative effectiveness of dabigatran and rivaroxaban versus warfarin for the treatment of non-valvular atrial fibrillation. *J Cardiol* 2017;69:868–76.
 150. Chan P-H, Hai J-J, Huang D, *et al.* Burden of upper gastrointestinal symptoms in patients prescribed dabigatran for stroke prevention. *SAGE Open Med* 2016;4.
 151. Hohnloser SH, Basic E, Nabauer M. Comparative risk of major bleeding with new oral anticoagulants (NOACs) and phenprocoumon in patients with atrial fibrillation: a post-marketing surveillance study. *Clin Res Cardiol* 2017;106:618–28.
 152. Saji N, Kimura K, Tateishi Y, *et al.* Safety and efficacy of non-vitamin K oral anticoagulant treatment compared with warfarin in patients with non-valvular atrial fibrillation who develop acute ischemic stroke or transient ischemic attack: a multicenter prospective cohort study (daVinci study). *J Thromb Thrombolysis* 2016;42:453–62.
 153. Korenstra J, Wijnlt EPJ, Veeger NJGM, *et al.* Effectiveness and safety of dabigatran versus acenocoumarol in 'real-world' patients with atrial fibrillation. *Europace* 2016;18:1319–27.
 154. Naganuma M, Shiga T, Nagao T, *et al.* Effectiveness and safety of dabigatran versus warfarin in "real-world" Japanese patients with atrial fibrillation: single-center observational study. *J Arrhythm* 2017;33:107–10.
 155. Sunbul M, Oguz M, Dogan Z, *et al.* Heart failure and mortality in patients with nonvalvular atrial fibrillation started on novel oral anticoagulant therapy: a single-center experience. *Clin Appl Thromb Hemost* 2017;23:454–9.
 156. Yao X, Abraham NS, Sangaralingham LR, *et al.* Effectiveness and safety of dabigatran, rivaroxaban, and apixaban versus warfarin in nonvalvular atrial fibrillation. *J Am Heart Assoc* 2016;5:e003725.
 157. Ezekowitz MD, Eikelboom J, Oldgren J, *et al.* Long-Term evaluation of dabigatran 150 vs. 110 Mg twice a day in patients with non-valvular atrial fibrillation. *Europace* 2016;18:973–8.
 158. Camm AJ, Amarencio P, Haas S, *et al.* XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. *Eur Heart J* 2016;37:1145–53.
 159. Márquez-Contreras E, Martell-Claros N, Gil-Guillén V, *et al.* Quality of life with rivaroxaban in patients with non-valvular atrial fibrillation by therapeutic compliance. *Qual Life Res* 2017;26:647–54.
 160. Tepper PG, Liu X, Hamilton M, *et al.* Ischemic stroke in nonvalvular atrial fibrillation at warfarin initiation: assessment via a large insurance database. *Stroke* 2017;48.
 161. Li XY, Deitelzweig S, Keshishian A, *et al.* Effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation patients in "real-world" clinical practice. *Thromb Haemostasis* 2017;117:1072–82.
 162. Márquez-Contreras E, Martell-Carlos N, Gil-Guillén V, *et al.* Therapeutic compliance with rivaroxaban in preventing stroke in patients with non-valvular atrial fibrillation: CUMRIVAFA study. *Curr Med Res Opin* 2016;32:2013–20.
 163. Larsen TB, Skjøth F, Nielsen PB, *et al.* Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and

- warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. *BMJ* 2016;353.
164. Kilickiran Avci B, Vatan B, Ozden Tok O, *et al.* The trends in utilizing Nonvitamin K antagonist oral anticoagulants in patients with nonvalvular atrial fibrillation: a real-life experience. *Clin Appl Thromb Hemost* 2016;22:785–91.
 165. Inoue H, Uchiyama S, Atarashi H, *et al.* Post-Marketing surveillance on the long-term use of dabigatran in Japanese patients with nonvalvular atrial fibrillation: preliminary report of the J-dabigatran surveillance. *J Arrhythm* 2016;32:145–50.
 166. Chan P-H, Li W-H, Hai J-J, *et al.* Gastrointestinal haemorrhage in atrial fibrillation patients: impact of quality of anticoagulation control. *Eur Heart J Cardiovasc Pharmacother* 2015;1:265–72.
 167. Laliberté F, Cloutier M, Crivera C, *et al.* Effects of rivaroxaban versus warfarin on hospitalization days and other health care resource utilization in patients with nonvalvular atrial fibrillation: an observational study from a cohort of matched users. *Clin Ther* 2015;37:554–62.
 168. Lee S-J, Uhm J-S, Kim J-Y, *et al.* The safety and efficacy of vitamin K antagonist in patients with atrial fibrillation and liver cirrhosis. *Int J Cardiol* 2015;180:185–91.
 169. Lau WCY, Chan EW, Cheung C-L, *et al.* Association between dabigatran vs warfarin and risk of osteoporotic fractures among patients with nonvalvular atrial fibrillation. *JAMA* 2017;317:1151–8.
 170. Ho C-W, Ho M-H, Chan P-H, *et al.* Ischemic stroke and intracranial hemorrhage with aspirin, dabigatran, and warfarin: impact of quality of anticoagulation control. *Stroke* 2015;46:23–30.
 171. Chan P-H, Hai J, Yeung C-Y, *et al.* Benefit of anticoagulation therapy in Hyperthyroidism-Related atrial fibrillation. *Clin Cardiol* 2015;38:476–82.
 172. Chao T-F, Liu C-J, Tuan T-C, *et al.* Rate-control treatment and mortality in atrial fibrillation. *Circulation* 2015;132:1604–12.
 173. Pastori D, Farcomeni A, Bucci T, *et al.* Digoxin treatment is associated with increased total and cardiovascular mortality in anticoagulated patients with atrial fibrillation. *Int J Cardiol* 2015;180:1–5.
 174. Chen P-C, Lip GYH, Yeh G, *et al.* Risk of bleeding and stroke with oral anticoagulation and antiplatelet therapy in patients with atrial fibrillation in Taiwan: a nationwide cohort study. *PLoS One* 2015;10:e125257.
 175. Engelberger RP, Noll G, Schmidt D, *et al.* Initiation of rivaroxaban in patients with nonvalvular atrial fibrillation at the primary care level: the Swiss therapy in atrial fibrillation for the regulation of coagulation (STAR) study. *Eur J Intern Med* 2015;26:508–14.
 176. Li H, Liu Y, Zhang P, *et al.* Analysis of normalized anticoagulant therapy for patients with non-valvular atrial fibrillation in clinical application [In Chinese]. *Pract J Med Pharm* 2016;33:584–5.
 177. Tung JM, Mamdani MM, Juurlink DN, *et al.* Rates of ischemic stroke during warfarin treatment for atrial fibrillation. *Stroke* 2015;46:1120–2.
 178. Wu Y-L, Saver JL, Chen P-C, *et al.* Effect of statin use on clinical outcomes in ischemic stroke patients with atrial fibrillation. *Medicine* 2017;96:e5918.
 179. Kodani E, Atarashi H, Inoue H, *et al.* Beneficial effect of non-vitamin K antagonist oral anticoagulants in patients with nonvalvular atrial fibrillation- Results of the J-RHYTHM registry 2. *Circ J* 2016;80:843–51.
 180. Yamashita T, Inoue H, Okumura K, *et al.* Warfarin anticoagulation intensity in Japanese nonvalvular atrial fibrillation patients: a J-RHYTHM registry analysis. *J Cardiol* 2015;65:175–7.
 181. Kumagai N, Nasser JA, Inoue H, *et al.* Effect of addition of a statin to warfarin on thromboembolic events in Japanese patients with nonvalvular atrial fibrillation and diabetes mellitus. *Am J Cardiol* 2017;120:230–5.
 182. Blin P, Dureau-Pournin C, Lassalle R, *et al.* A population database study of outcomes associated with vitamin K antagonists in atrial fibrillation before DOAC. *Br J Clin Pharmacol* 2016;81:569–78.
 183. Piccini JP, Simon DN, Steinberg BA, *et al.* Differences in clinical and functional outcomes of atrial fibrillation in women and men: two-year results from the ORBIT-AF registry. *JAMA Cardiol* 2016;1:282–91.
 184. Allen LA, Fonarow GC, Simon DN, *et al.* Digoxin use and subsequent outcomes among patients in a contemporary atrial fibrillation cohort. *J Am Coll Cardiol* 2015;65:2691–8.
 185. Genovesi S, Rossi E, Gallieni M, *et al.* Warfarin use, mortality, bleeding and stroke in haemodialysis patients with atrial fibrillation. *Nephrol Dial Transplant* 2015;30:491–8.
 186. Qin D, Leef G, Alam MB, *et al.* Comparative effectiveness of antiarrhythmic drugs for rhythm control of atrial fibrillation. *J Cardiol* 2016;67:471–6.
 187. Purmah Y, Proietti M, Laroche C, *et al.* Rate vs. rhythm control and adverse outcomes among European patients with atrial fibrillation. *Europace* 2018;20:243–52.
 188. Pasca S, Venturelli U, Bertone A, *et al.* Direct oral anticoagulants for very elderly people with atrial fibrillation: efficacy and safe enough? *Clin Appl Thromb Hemost* 2017;23:58–63.
 189. Nielsen PB, Skjøth F, Søgaard M, *et al.* Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. *BMJ* 2017;356.
 190. Bo M, Li Puma F, Badinella Martini M, *et al.* Effects of oral anticoagulant therapy in older medical in-patients with atrial fibrillation: a prospective cohort observational study. *Aging Clin Exp Res* 2017;29:491–7.
 191. Jacobs V, May HT, Bair TL, *et al.* Long-term population-based cerebral ischemic event and cognitive outcomes of direct oral anticoagulants compared with warfarin among long-term anticoagulated patients for atrial fibrillation. *Am J Cardiol* 2016;118:210–4.
 192. Lip GYH, Pan X, Kamble S, *et al.* Major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a "real-world" observational study in the United States. *Int J Clin Pract* 2016;70:752–63.
 193. Hanon O, Chaussade E, Gueranger P, *et al.* Patient-Reported treatment satisfaction with rivaroxaban for stroke prevention in atrial fibrillation. A French observational study, the safari study. *PLoS One* 2016;11:e166218.
 194. Patti G, Lucerna M, Pecun L, *et al.* Thromboembolic Risk, Bleeding Outcomes and Effect of Different Antithrombotic Strategies in Very Elderly Patients With Atrial Fibrillation: A Sub-Analysis From the PREFER in AF (PREvention of Thromboembolic Events-European Registry in Atrial Fibrillation). *J Am Heart Assoc* 2017;6:e005657.
 195. Graham DJ, Reichman ME, Wernecke M, *et al.* Stroke, bleeding, and mortality risks in elderly Medicare beneficiaries treated with dabigatran or rivaroxaban for nonvalvular atrial fibrillation. *JAMA Intern Med* 2016;176:1662–71.
 196. Tampieri A, Cipriano V, Mucci F, *et al.* Safety of cardioversion in atrial fibrillation lasting less than 48 h without post-procedural anticoagulation in patients at low cardioembolic risk. *Intern Emerg Med* 2018;13:87–93.
 197. Lee S-J, Sung J-H, Kim J-B, *et al.* The safety and efficacy of vitamin K antagonist in atrial fibrillation patients with previous ulcer bleeding: long-term results from a multicenter study. *Medicine* 2016;95:e5467.
 198. Stolk LM, de Vries F, Ebbelaar C, *et al.* Risk of myocardial infarction in patients with atrial fibrillation using vitamin K antagonists, aspirin or direct acting oral anticoagulants. *Br J Clin Pharmacol* 2017;83:1835–43.
 199. Boriani G, Laroche C, Diemberger I, *et al.* 'Real-world' management and outcomes of patients with paroxysmal vs. non-paroxysmal atrial fibrillation in Europe: the EURObservational research Programme-Atrial fibrillation (EORP-AF) general pilot registry. *Europace* 2016;18:648.1–57.
 200. Eisen A, Ruff CT, Braunwald E, *et al.* Digoxin use and subsequent clinical outcomes in patients with atrial fibrillation with or without heart failure in the engage AF-TIMI 48 trial. *J Am Heart Assoc* 2017;6:e006035.
 201. Wan L, Deng L. Analysis of Anticoagulant Efficacy and Safety of dabigatran combined with clopidogrel in treatment of NVAF [In Chinese]. *Mod Hosp* 2018;18:536–8.
 202. Jian F. The analysis of efficacy and adverse effects of dabigatran in treating NVAF [In Chinese]. *China Pract Med* 2017;12:168–70.
 203. Gao DS. Therapeutic effect of different intensity anticoagulant therapy for chronic non-valvular atrial fibrillation in elderly patients [In Chinese]. *Guide China Med* 2018;16:108–9.
 204. Wang Y. Clinical observation of different INR on elderly patients with stable coronary heart disease complicated with atrial fibrillation [In Chinese]. *J Aerosp Med* 2018;29:317–9.
 205. Zhang DM, Zhang HM. Clinical observation of different INR on elderly patients with stable coronary heart disease complicated with atrial fibrillation [In Chinese]. *Chongqing Med* 2017;46:3420–1.
 206. Hasigaowa CZC, Liu DH, Zhang Y W. Effects of Rivaroxaban and Warfarin on D-dimer and NT-proBNP Levels in Elderly Patients with NVAF [In Chinese]. *Prog Mod Biomed* 2017;17:6291–4.
 207. Chen L, Gong YX, Zhang XL. Clinical Effect in Treating Non-valvular Atrial Fibrillation Patients with Advanced Age (>80 Years Old): a Comparison between Rivaroxaban and Warfarin [In Chinese]. *Pract J Card Cereb Pneurol Vasc Dis* 2018;26:55–8.
 208. Chen L, Zhong SQ, Zhong HJ, *et al.* Effect of Maixuekang Capsule on thromboembolism in patients with non-valvular atrial fibrillation [In Chinese]. *Chin J Mod Drug Appl* 2018;12:86–7.

209. Li D, Yue MZ. Clinical observation of Tongluo Dingxin Recipe in the treatment of blood stasis type of non-valvular atrial fibrillation and its effect on coagulation [In Chinese]. *Yunnan J Tradit Chin Med Mater Med* 2018;39:48–9.
210. Yu P. Clinical observation and safety evaluation of modified Xuefu Zhuyu decoction combined with dabigatran etexilate in the treatment of non - valvular atrial fibrillation. *Inform Tradit Chin Med* 2018;35:108–10.
211. De With RR, Rienstra M, Smit MD, *et al.* Targeted therapy of underlying conditions improves quality of life in patients with persistent atrial fibrillation: results of the RACE 3 study. *Europace* 2019;21:563–71.
212. Ezekowitz MD, Pollack CV, Halperin JL, *et al.* Apixaban compared to heparin/vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion: the EMANATE trial. *Eur Heart J* 2018;39:2959–71.
213. Li XL, Lu Y, Yin JF, *et al.* Genotype-Based anticoagulant therapy with warfarin for atrial fibrillation. *Int J Clin Exp Med* 2017;10:14056–62.
214. Yamashita T, Ikeda T, Akita Y. Comparison of heart rate reduction effect and safety between bisoprolol transdermal patch and bisoprolol fumarate oral formulation in Japanese patients with persistent/permanent atrial fibrillation (BISONO-AF study). *J Cardiol* 2019;73:386–93.
215. Bartlett JW, Renner E, Moulund E, *et al.* Clinical safety outcomes in patients with nonvalvular atrial fibrillation on rivaroxaban and diltiazem. *Ann Pharmacother* 2019;53:21–7.
216. Andersson NW, Svanström H, Lund M, *et al.* Comparative effectiveness and safety of apixaban, dabigatran, and rivaroxaban in patients with non-valvular atrial fibrillation. *Int J Cardiol* 2018;268:113–9.
217. Deitelzweig S, Luo X, Gupta K, *et al.* Comparison of effectiveness and safety of treatment with apixaban vs. other oral anticoagulants among elderly nonvalvular atrial fibrillation patients. *Curr Med Res Opin* 2017;33:1745–54.
218. Friberg L, Oldgren J. Efficacy and safety of non-vitamin K antagonist oral anticoagulants compared with warfarin in patients with atrial fibrillation. *Open Heart* 2017;4:e682.
219. Hernandez I, Zhang Y, Saba S. Comparison of the effectiveness and safety of apixaban, dabigatran, rivaroxaban, and warfarin in newly diagnosed atrial fibrillation. *Am J Cardiol* 2017;120:1813–9.
220. Pohjantähti-Maaroos H, Hyppölä H, Lekkala M, *et al.* Intravenous vernakalant in comparison with intravenous flecainide in the cardioversion of recent-onset atrial fibrillation. *Eur Heart J* 2019;8:114–20.
221. Koretsune Y, Yamashita T, Yasaka M, *et al.* Comparative effectiveness and safety of warfarin and dabigatran in patients with non-valvular atrial fibrillation in Japan: a claims database analysis. *J Cardiol* 2019;73:204–9.
222. Lai K-C, Chen S-J, Lin C-S, *et al.* Digoxin and amiodarone on the risk of ischemic stroke in atrial fibrillation: an observational study. *Front Pharmacol* 2018;9:448.
223. Li W-H, Huang D, Chiang C-E, *et al.* Efficacy and safety of dabigatran, rivaroxaban, and warfarin for stroke prevention in Chinese patients with atrial fibrillation: the Hong Kong atrial fibrillation project. *Clin Cardiol* 2017;40:222–9.
224. Link MS, Giugliano RP, Ruff CT, *et al.* Stroke and mortality risk in patients with various patterns of atrial fibrillation: results from the engage AF-TIMI 48 trial (effective anticoagulation with factor Xa next generation in atrial Fibrillation-Thrombolysis in myocardial infarction 48). *Circ Arrhythm Electrophysiol* 2017;10:e004267.
225. Lip GYH, Skjøth F, Nielsen PB, *et al.* Effectiveness and safety of standard-dose Nonvitamin K antagonist oral anticoagulants and warfarin among patients with atrial fibrillation with a single stroke risk factor: a nationwide cohort study. *JAMA Cardiol* 2017;2:872–81.
226. Noseworthy PA, Yao X, Gersh BJ, *et al.* Long-Term stroke and bleeding risk in patients with atrial fibrillation treated with oral anticoagulants in contemporary practice: providing evidence for shared decision-making. *Int J Cardiol* 2017;245:174–7.
227. Lip GYH, Keshishian A, Li X, *et al.* Effectiveness and safety of oral anticoagulants among nonvalvular atrial fibrillation patients. *Stroke* 2018;49:2933–44.
228. Martinez BK, Bunz TJ, Eriksson D, *et al.* Effectiveness and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and heart failure. *ESC Heart Fail* 2019;6:10–15.
229. Gieling EM, van den Ham HA, van Onzenoort H, *et al.* Risk of major bleeding and stroke associated with the use of vitamin K antagonists, nonvitamin K antagonist oral anticoagulants and aspirin in patients with atrial fibrillation: a cohort study. *Br J Clin Pharmacol* 2017;83:1844–59.
230. Go AS, Singer DE, Toh S, *et al.* Outcomes of dabigatran and warfarin for atrial fibrillation in contemporary practice: a retrospective cohort study. *Ann Intern Med* 2017;167:845–54.
231. Forslund T, Wettermark B, Andersen M, *et al.* Stroke and bleeding with non-vitamin K antagonist oral anticoagulant or warfarin treatment in patients with non-valvular atrial fibrillation: a population-based cohort study. *Europace* 2018;20:420–8.
232. Själander S, Sjögren V, Renlund H, *et al.* Dabigatran, rivaroxaban and apixaban vs. high TTR warfarin in atrial fibrillation. *Thromb Res* 2018;167:113–8.
233. Corbalán R, Nicolau JC, López-Sendon J, *et al.* Edoxaban versus Warfarin in Latin American patients with atrial fibrillation: the ENGAGE AF-TIMI 48 trial. *J Am Coll Cardiol* 2018;72:1466–75.
234. Bae H-J, Heo JH, Jung K-H, *et al.* Antithrombotic treatments in patients with acute ischemic stroke and non-valvular atrial fibrillation before introduction of non-vitamin K antagonist oral anticoagulants into practice in Korea. *PLoS One* 2018;13:e0202803.